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CHAPER 1:  GENERAL INTRODUCTION 
 
 Since its isolation from pigs in 1930, influenza A virus has had devastating effects on 
the swine industry102.  In the United States, at least 25% of pigs have been found to be 
positive for antibodies against swine influenza virus at slaughter23.  Economic loss can be 
attributed to an increase in the time needed for pigs to reach market weight80.  Although 
several vaccines are currently on the market to combat influenza infection in swine, none are 
able to protect against all subtypes of the virus.  New virus reassortants continue to be 
isolated from the swine population, demonstrating the need for an improved method of 
vaccination against influenza virus in pigs62, 65, 124.   
 The focus of this thesis is to describe work done towards the development of a new 
vaccination method for influenza in swine.  Chapter 2 provides a general overview of 
influenza A virus including current vaccination methods in pigs.  Chapters 3 and 4 are 
written in journal article format and describe the author’s research experiments.  Chapter 5 
provides general conclusions for the author’s thesis.  
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CHAPER 2:  LITERATURE REVIEW 
 
Section 1: Introduction - Influenza A Virus 
Influenza A virus is known to infect a wide range of species including humans, swine, 
horses, tigers, dogs, whales, mink, and other animal species16, 73, 118.  Historical accounts of 
influenza epidemics date back to the 14th and 15th centuries, but swine influenza A virus was 
first isolated in 1930 from pigs, and human influenza A virus was first isolated in 1933 from 
ferrets88, 102, 107.  Since that time, much work has been done to characterize the virus and 
determine its mechanism of pathogenesis; however, more work is needed especially in the 
area of vaccine development.  
Disease caused by influenza A virus in mammals is characterized by the rapid onset 
of clinical symptoms including fever, coughing, dyspnea, lethargy, and pneumonia.  
Recovery following infection is rapid in the absence of secondary pathogens.  Occasionally, 
viral pneumonia is complicated by secondary infection and can lead to death23.  Several 
major influenza pandemics have occurred in the human population throughout history, 
including 1918, 1957, 1968 and 1977116.  Currently, various vaccines are available to combat 
influenza A virus infections in humans and animals including swine and horses.  However, 
due to the virus’s ability to undergo rapid change in its antigenic properties through antigenic 
drift and shift, a universal vaccine that is effective against many or all subtypes of the virus 
has yet to be developed23, 82, 100.  The following sections will briefly outline current 
classification of the virus, its mechanism of pathogenesis, host immune response to the virus, 
and current methods of vaccination. 
 
Section 2: Characterization and Classification 
Influenza A virus is a member of the family Orthomyxoviridae, genus influenza A virus133.  
It is a pleomorphic, enveloped virus with helical symmetry73.  The genome of influenza A is 
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approximately 13.6 kbp in size and consists of eight single-stranded, negative sense RNA 
segments12, 104.  Virus particles range in size from approximately 80 to 120 nm in diameter73.  
The eight gene segments in each virion encode a total of eleven known proteins: three viral 
polymerase subunits (PB2 from segment 1, PB1 from segment 2, and PA from segment 3); 
PB1-F2 from segment 2, a recently discovered protein that is thought to be involved in the 
induction of host cell death; hemagglutinin (HA) from segment 4, and neuraminidase (NA) 
from segment 6, both surface glycoproteins; nucleoprotein (NP) from segment 5 which binds 
and surrounds the viral RNA segments; matrix 1 (M1) from segment 7 which makes up a 
majority of the viral protein shell; matrix 2 (M2) from segment 7, a transmembrane protein 
which acts as a proton channel; nuclear export protein (NEP, formerly known as NS2) from 
segment 8; and non-structural protein 1 (NS1) from segment 8 which plays a role in evasion 
of the host immune response10, 13, 131, 133.  
Influenza A virus is one of  four genera in the family Orthomyxoviridae, and is 
differentiated from influenza B virus, influenza C virus, and thogotovirus based upon several 
characteristics including differences in NP and M1 protein identity, number of gene segments 
in each virion, and differences in host range73, 133.  Currently, sixteen different HA and nine 
different NA subtypes have been isolated from influenza A viruses in wild birds26.  Many of 
these HA and NA subtypes have only been found in avian species.  In humans, subtypes 
H1N1, H2N2, and H3N2 have been the predominate causes of disease, with subtypes H5N1, 
H7N7 and H9N2 causing fewer, more isolated cases of human disease59.      
 
HPAI vs. LPAI Viruses: 
As all known subtypes of influenza A viruses are found in wild birds, influenza A viruses 
have been categorized as either high pathogenic avian influenza (HPAI), low pathogenic 
avian influenza (LPAI), or nonpathogenic avian influenza (NPAI)2, 39, 108.  Many factors may 
play a role in determining viral pathogenicity, as several influenza viral RNA (vRNA) 
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segments have been shown to affect host range and virulence108.   However, it has been 
demonstrated that the amino acid sequence at the cleavage site of HA (discussed further in 
Section 3, below) is one major determinant of virulence.  HPAI viruses contain multiple 
basic amino acid residues at their HA cleavage site, while LPAI and NPAI typically have one 
arginine or lysine found at the carboxyl terminus of HA1 and one glycine at the amino 
terminus of HA239, 108.  To date, the only naturally occurring HPAI isolates have contained 
HA subtypes H5 or H7, and these HPAI viruses have occasionally crossed the species barrier 
into humans and other animals108, 118.    
 
Drift and Shift: 
Influenza viruses are known for their ability to rapidly change their antigenic properties, 
making it difficult to develop an efficient vaccination strategy against them.  These rapid 
antigenic changes are carried out by two main mechanisms, antigenic drift and shift.  
Antigenic drift refers to slight changes in the amino acid sequence of an antigenic domain 
within a viral gene.  Drift is commonly seen in the HA and NA genes of influenza viruses, 
and this is important as these two proteins have been shown to have an effect on host range 
and virulence of a virus43, 94.  Antigenic shift refers to the swapping of entire gene segments 
(genetic reassortment) between different virus strains during a coinfection of two or more 
viruses.  Any of the eight viral RNA segments can undergo shift, and segments can be shared 
between species109. 
 
Swine Influenza A Viruses: 
Three different subtypes of influenza A virus predominate in swine populations today, H1N1, 
H1N2, and H3N2, with genes originating from swine, human and avian influenza strains62.  
However, due to genetic reassortment, new strains are being isolated from swine herds 
throughout the world including the United States, Canada, and Europe47, 62, 65, 124. 
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Section 3: Disease and Pathogenesis 
Aquatic avian species are the natural reservoir of influenza A viruses73.   These viruses do 
not generally cause clinical disease in wild fowl, but the virus is transmitted to other animal 
species from aquatic birds where it can cause disease78.  The virus typically replicates in 
intestinal epithelial cells of wild birds and is excreted into the environment in the feces where 
it can be transmitted to other animals, importantly domestic birds and livestock73, 78.   
Swine influenza A virus typically causes an acute, respiratory illness that can affect 
pigs of any age.  Symptoms may include fever, coughing, rhinitis, pharyngitis, and 
pneumonia, with rapid onset and recovery.  In a herd, it is common to see up to 100% 
morbidity, but low mortality rates22, 23. 
 
Attachment:  
Influenza virus infection begins when the virus binds to host cell surface receptors 
(sialyloligosaccharides) via viral hemagglutinin (HA)112, 137.  The HA glycoprotein exists on 
the surface of each virion as a homotrimer.  Specific host cell proteases cleave the HA 
glycoprotein (designated HA0) at a conserved arginine residue into two subunits, HA1 and 
HA2, which remain linked together by a disulfide bond96, 108, 110.  For low or nonpathogenic 
viruses, HA is cleaved extracellularly by trypsin-like proteases that are expressed only by a 
few cell or tissue types, preventing the systemic spread of the virus108.  The HA of 
pathogenic viruses is cleaved intracellularly by subtilisin-like proteases, enabling them to 
immediately infect other cells upon budding from their host cell108.  Cleavage of HA0 
facilitates viral entry into host cells by exposing the sialic acid binding pocket on HA1 and 
membrane fusion peptide on HA2, and allowing HA to undergo the conformational change 
necessary to be activated by the low pH of cellular endosomes69, 108.   
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Receptor Strength and Specificity: 
Receptor binding strength and specificity of HA play a large role in determining the host 
range of a specific virus.  The position and number of glycans on an HA molecule can vary 
from virus strain to strain42, 68.  This variation in glycosylation pattern can influence the 
virus’s host range, and can also play a role in the virus’s requirement for neuraminidase 
(NA)94.  Neuraminidase, influenza’s other major surface glycoprotein, also recognizes host 
cell sialyloligosaccharides, but acts in opposition to HA, cleaving  linkages between sialic 
acid and its adjacent sugar residue in order to aid in the release of progeny virions during 
budding33, 105.  Work done by Mishin et al68 has suggested that specific HA glycosylation 
patterns can reduce a virus’s need for NA activity.   
It has also been determined that a virus’s receptor binding specificity is strongly 
correlated with the amino acid at position 226 of the HA protein.  If glutamine is located at 
position 226, then HA will preferentially bind to 5-N-acetylneuraminic acid containing α–
(2,3) linkages.   However, if leucine is located at position 226, then HA will preferentially 
bind to receptors containing α–(2,6) linkages136, 137.  Human influenza A viruses typically 
prefer receptors with α–(2,6) linkages, as human epithelial cells lining the trachea possess 
primarily NeuAcα2,6Gal sialyloligosaccharides, while avian viruses prefer receptors with α–
(2,3) linkages as NeuAcα2,3Gal sialyloligosaccharides are predominant in the intestinal tract 
of wild birds112.  Pigs, however, have been shown to possess both NeuAcα2,3Gal and 
NeuAcα2,6Gal sialyloligosaccharides on the epithelial cells lining the trachea, suggesting 
that they can efficiently support infection of both avian and human strains of influenza A 
virus43.   
 
Entry: 
After the virus has bound to its host receptor, it is taken into host cell endosomes139.             
The low pH of the endosome causes HA to undergo a conformational change that leads to 
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fusion of the endosomal membrane with the viral envelope39.  Matrix 2 is a proton channel 
spanning the viral membrane that allows the inner portion of the virion to be exposed to the 
low pH of the endosome, causing the viral ribonucleoproteins (vRNPs) to detach from the 
M1 viral protein shell and move into the cell cytoplasm39.  The vRNPs are then transported 
into the host cell nucleus, where viral RNA undergoes both transcription to form viral mRNA 
for protein synthesis, and replication to make copies of the viral RNA (vRNA) segments to 
be packaged in new virions34, 74.      
 
RNA Replication and Protein Synthesis: 
The vRNA polymerase responsible for both transcription of viral mRNA and viral genome 
replication is a complex of three proteins: polymerase B1 (PB1), polymerase B2 (PB2), and 
polymerase A (PA)40.  Polymerase B1 is believed to be responsible for RNA-dependent-
RNA-polymerase activity, while PB2 is thought to be involved in mRNA transcription 
initiation through capping of viral mRNA5, 9, 74.  The role of the PA protein is less clearly 
understood.  Cloned complementary DNA (cDNA) studies have demonstrated that PA 
expression is correlated with a degradation of other proteins, both cellular and viral, but 
whether this role is significant in an actual viral infection has yet to be determined98.  Recent 
work done by Huarte et al41 showed that viruses containing mutations in the PA gene, 
particularly at threonine 157, had altered PA protease activity and overall viral 
complementary RNA (cRNA) synthesis.  
The viral polymerase complex must transcribe viral mRNA to make proteins, and 
must also make full length cRNA in order to replicate viral vRNAs for packaging into new 
virions.  It has been determined that transcription into mRNA is initiated with capped RNA 
priming using host cell mRNA, whereas transcription of cRNA to make full length vRNA is 
primer-independent35, 86, 87, 103.  All eight influenza virus vRNAs consist of a coding region 
flanked on each end by untranslated regions (UTRs) containing sequences that are highly 
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conserved between vRNAs and between different virus strains58.  Studies have shown that 
sequences within the 5’ UTR of the viral mRNA segments regulate the preferential 
translation of viral mRNAs over host cell mRNAs30, 85.  It has also been shown that the host 
cell RNA-binding protein GRSF-1 interacts with portions of the 5’ UTR on viral mRNAs to 
influence viral protein synthesis, although the exact mechanism of this interaction is 
unknown85.  
Once vRNPs are in the nucleus, viral transcription to make 5’-capped, 3’-
polyadenylated mRNAs begins4.  Upon viral infection of cells, host mRNA translation is 
blocked at both the initiation and elongation steps, as cellular mRNA remains bound to 
ribosomes48.  One host cell protein that has been shown to play a significant role in viral 
mRNA translation is p58IPK.  Upon viral infection, several interferon-induced host cell 
proteins begin to work to combat viral infection, including PKR.  p58IPK inhibits PKR 
(explained further in Section 4, below), aiding in viral mRNA transcription32.  When a 
sufficient amount of viral mRNA has been produced, viral transcription is downregulated, 
and viral genome replication commences.   Influenza virus nucleoprotein (NP) plays an 
important role in this switching from mRNA production to cRNA and vRNA production by a 
mechanism thought to involve the direct interaction of NP with the PB2 subunit of the 
polymerase complex8.  
While cRNA and vRNA are being replicated in the nucleus, viral mRNA is being 
translated into proteins in the cytoplasm in preparation for assembly of new virions.  Matrix l 
protein, the major inner structural protein of influenza virus, also plays an important role in 
the progression from genome replication to virus assembly.  Once M1 mRNA is translated 
into protein in the cytoplasm, the protein enters the nucleus and binds to newly formed 
ribonucleoproteins (RNPs) to facilitate their exit into the cytoplasm, and to prevent them 
from re-entering the nucleus60.  In addition to the M1 protein, it has been suggested that the 
nuclear export protein (NEP) plays a critical role in the export of newly formed RNPs from 
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the nucleus to the cytoplasm77.  With all viral proteins now in the cytoplasm, the process of 
virus assembly and budding is able to proceed. 
 
Control of Host Gene Expression: 
During influenza virus infection, host cell gene expression is drastically changed.  Studies 
using DNA microarray analysis of over 4,500 cellular genes demonstrated that many host 
genes are regulated during influenza virus infection both dependently and independently of 
viral replication.  Importantly, some genes that are downregulated include genes involved in 
progression of the cell cycle, several transcriptional regulators, and genes involved in the 
ubiquitin pathway, while the metallothionein genes are among those that are upregulated31.  
The exact mechanisms used by influenza virus in controlling gene regulation have not been 
determined, but suggestions as to the probable cause of this altered gene expression included 
transcriptional regulation by viral proteins as well as the shift in stability of host cell mRNA 
following viral infection31.  One viral protein that has been shown to play a role in the control 
of host protein expression is NS1.  Work done by Fernandez-Sesma et al25 demonstrated that 
the presence of NS1 protein in influenza virus prevents the production of interferon-alpha 
(IFN-α) and interferon-beta (IFN-β), and inhibits the maturation of dendritic cells, thereby 
downregulating the T-cell response.    
 
Virion Assembly and Budding: 
During virion assembly in host cells, all of the necessary components must be present in each 
virion in order for the virus to successfully infect new cells.  A sufficient amount of HA is 
necessary on the surface of each virus particle to facilitate attachment and entry into a host 
cell.  Studies have demonstrated that during virus assembly, HA molecules cluster together in 
host cell lipid rafts.  It has been suggested that this clustering allows for the necessary 
amount of HA to be expressed on each virion for infection of new host cells114.   
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For the eight vRNAs, it has been reported that cis-acting packaging signals are found 
within the UTRs of the segments, and that these signals extend into the coding region of the 
segments58, 71.  It has been suggested that the PB2 vRNA segment may be involved in the 
assimilation of the other seven vRNA segments into budding virions71.   It has also been 
shown that vRNAs are specifically arranged in new virions.  Seven segments surround the 
eighth segment in a circular or cubodial pattern, and all eight segments are associated with 
the budding end of a new virion75.  
As new virions begin to bud out of their host cell, NA recognizes host sialic acid 
receptors and functions to cleave α-2,3 or α-2,6 ketosidic linkages between HA and its cell 
surface sialic acid receptor allowing the new virions to completely bud out of the plasma 
membrane and infect new host cells69.   
 
Section 4: Immune Response 
Immunopathology: 
After influenza virus enters a new host, virally infected cells as well as antigen presenting 
cells that have encountered viral proteins are stimulated to produce a variety of cytokines, 
leading to the induction of cytokine-regulated proteins.  Interferons α and β (IFN- α, IFN-β) 
stimulate the production of protein kinase, PKR (also know as DAI, dsI or P1/eIF-2 kinase, 
P68), which is then activated by dsRNA to phosphorylate eukaryotic initiation factor 2 alpha 
(eIF-2α), leading to the downregulation of protein synthesis in the host cell7, 27, 49, 119.  
Influenza virus has developed a mechanism to combat this host cell strategy of attempting to 
shut down viral RNA synthesis by interacting with the host protein P58IPK using a not yet 
characterized mechanism that inhibits PKR from phosphorylating eIF-2α, allowing viral 
protein synthesis to occur32. 
Studies in pigs have shown that IFN-α, tumor necrosis factor- α (TNF-α), and 
interleukin-1 (IL-1) are three cytokines that play an important role in the host’s immune 
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response to influenza virus infection.  All three cytokines are able to induce non-specific 
antiviral effects as well as fever, and TNF-α and IL-1 have been shown to play an important 
role in the migration of large numbers of neutrophils and monocytes to the lungs as part of 
the inflammatory response126.  Based on studies of cytokine expression in pigs following 
influenza virus challenge, it has been suggested that the virus induces a strong cytokine 
response in the lungs.  This cytokine response is an effect of viral infection, resulting in a 
more severe respiratory infection than what is seen with other swine respiratory viruses 
including porcine respiratory coronavirus and some isolates of porcine reproductive and 
respiratory syndrome virus125.  A study demonstrated that pigs vaccinated with either a 
heterologous or homologous vaccine that were not completely protected from virus challenge 
still had markedly reduced levels of IFN-α, TNF-α, IL-1, IL-6 and IL-8 in their lungs 
compared to unvaccinated, challenged pigs127.  In the same study, pigs vaccinated and 
completely protected after challenge showed a reduction in neutrophil infiltration to the lungs 
and even lower levels of IFN-α, IL-6 and IL-8 than vaccinated pigs that were not protected, 
while levels of TNF- α and IL-1 were approximately the same in both groups.  This 
demonstrates the differences in cytokine profiles between vaccinated and unvaccinated pigs.    
Although virus virulence has been shown to be affected by the strength and 
specificity of influenza HA binding to its host cell receptor, other mechanisms of virulence 
relating to the virus’s ability to overcome host immune response have been demonstrated.  
Work done by Seo et al101, suggested that the high level of virulence expressed by H5N1 
influenza viruses may be due to the ability of their NS1 gene to overcome the antiviral effects 
of various host cell cytokines including IFN-α, IFN-γ, and TNF-α.  Pathogenic H5N1 viruses 
were shown to contain a glutamic acid residue at position 92 in the NS1 gene, whereas 
nonpathogenic viruses contain an aspartic acid residue at this position.  Pigs inoculated with 
a recombinant virus containing the NS1 gene from the H5N1 virus showed an increased viral 
load in the lungs, increased body temperature, and increased length of viral shedding when 
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compared to pigs inoculated with an H1N1 virus containing the H1 NS1 gene101.  Work done 
by Li et al57 suggested that the amino acid residue at position 149 of the NS1 gene is 
responsible for virulence phenotype in chickens.  
 
Humoral and Cell Mediated Immune Response:  
In newborn piglets, immunoglobulin acquired from their dam through colostrum in the first 
24 to 36 hours after birth acts to protect them until their adaptive immune responses have 
developed72.  This acquired or maternally derived antibody (MDA) can have a number of 
effects on the immune response of piglets exposed to a variety of pathogens including 
influenza virus.  Work done by Loeffen et al61 examined the effects of MDA on influenza 
virus excretion, antibody production and T-cell responses in piglets experimentally 
challenged with a homologous H1N1 virus.  It was shown that piglets with MDA were 
incompletely protected from homologous challenge, and they shed virus longer and 
demonstrated an inhibited immune response against a second infection when compared to 
piglets without MDA, although these results may be relevant only for piglets with similar 
levels of MDA as seen in this study.  A study performed by Kitikoon el al52 demonstrated 
that MDA does not protect piglets from heterologous virus challenge, and may actually 
enhance disease.   
 Several studies have been conducted to evaluate the specific antibody responses of 
pigs after infection with various strains of influenza virus.  Work done by Kim et al50 
evaluated the antibody response of 5-week-old pigs experimentally infected with either an 
H1N1 or H3N2 SIV isolate.  Infected pigs developed antibodies to the virus they were 
infected with by 7 days post infection (PI), whereas pigs vaccinated with a commercial 
bivalent vaccine did not show an antibody response by hemagglutination-inhibition (HI) 
assay until two weeks after a second vaccination (4 weeks after first vaccination).  Specific 
antibody profiles of experimentally infected pigs were also examined.  It was shown that IgM 
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antibodies specific for HA were present in all infected pigs at 7 days PI, whereas IgG 
antibodies specific for HA, although present in some pigs by 7 days PI, did not show up in all 
pigs until 14 days PI and could be detected until termination of the study (28 days PI).  The 
presence of antibodies against several other influenza proteins was also evaluated.  No IgM 
antibodies specific for NA or M1 proteins could be detected by western blot in any of the 
pigs throughout the study, but IgG antibodies specific for NA and M1 were detected in most 
pigs by 14 days PI and all pigs at 28 days PI.  IgM antibodies specific for NP, NS1 and NEP 
(NS2) proteins were detected in all pigs by 7 days PI, and could be detected in most pigs 
until 28 days PI.  IgG antibodies specific for NP, NS1 and NEP (NS2) proteins were detected 
in all pigs from 7 days PI until 28 days PI. 
 Work done by Larsen et al53 evaluated the serum and mucosal antibody responses of 
pigs to experimental infection with an H1N1 SIV isolate.  It was shown that after infection, 
virus-specific serum IgG levels were two to four times higher than serum IgA levels at all 
time points during the study (7 to 56 days post initial infection).  The opposite was observed 
in both the upper and lower airways, with virus-specific IgA levels being higher than IgG 
levels in both areas throughout the study.  Pigs were infected for a second time 42 days after 
initial infection with the homologous virus, and neither virus-specific IgG nor IgA levels 
increased dramatically in either the serum or lower airway, but did increase substantially in 
the upper airway.  The location of IgG and IgA producing cells as well as IFN-γ producing 
cells was also evaluated.  It was shown that the primary location of IgG and IgA producing 
cells was the nasal mucosa, with more IgA-producing cells than IgG-producing cells being 
detected.  The primary location of IFN-γ producing cells was the tracheobronchial lymph 
nodes and spleen. 
 Other work has been done to evaluate the differences in both humoral and cellular 
immune responses between pigs infected with heterologous versus homologous strains of 
influenza virus.  Heinen et al36 evaluated the humoral and cellular immune responses of pigs 
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experimentally infected at two time points with either homologous (H3N2) or heterologous 
(H1N1 and H3N2) virus strains.  After first infection with either H1N1 or H3N2, both groups 
of pigs developed HI titers against their challenge virus, but not against the heterologous 
virus.  After a second infection, the group of pigs initially infected with H1N1 and then 
infected with the heterologous H3N2 SIV strain (group Het-I) developed strong HI titers 
against the H3N2 strain, and they also showed a slight increase in HI titers against the H1N1 
strain.  An M2e-specific ELISA was also used to show that after second infection, pigs in the 
Het-I group developed high levels of serum IgG against the M2e protein.  This high level of 
response was not seen in the group of pigs infected both times with H3N2 SIV (group Hom-
I).  The cellular immune response was characterized by an influx of neutrophils into the lungs 
by 2 days after first infection in both groups.  After second infection, the level of infiltration 
decreased in group Het-I and was not seen in group Hom-I.  Also after approximately 2 days 
following the first infection, both groups had an increase in natural killer (NK) cells, at 4 to 
11 days an increase in T-helper (Th) cells, and at 8 days a large increase in cytotoxic 
lymphocytes (CTLs) corresponding to a drop in NK cells.  After the second infection, a 
further increase in CTLs was observed in group Het-I, but not in group Hom-I, therefore it 
was suggested that in order for a vaccine to induce heterologous protection against various 
influenza virus strains, it should elicit a CTL (CD8+ T-cell) response. 
 
Section 5: Vaccination 
The development of a safe, efficacious vaccine strategy to combat influenza virus infections 
in both humans and animals has posed a problem for decades.  As early as the 1950s 
researchers saw the difficulty in developing a universal influenza vaccine due to the virus’s 
ability to undergo antigenic drift and shift138.  Since that time, much work has been done in 
an attempt to improve the current influenza vaccination methods.   
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Inactivated Whole and Subunit Vaccines: 
One of the early methods of vaccinating against influenza virus in humans used whole, 
formalin inactivated virus particles grown in embryonated chicken eggs97.  Inactivated 
vaccines are also used to vaccinate swine against influenza A virus.  A study conducted by 
Heinen et al38 evaluated the immune response of a group of pigs vaccinated with a 
commercial spilt vaccine (primary component of the spilt vaccine was HA protein) from a 
human H3N2 virus then challenged with a swine H3N2 virus currently circulating in the 
swine population versus a group of pigs inoculated and then challenged with the same swine 
H3N2 virus.  The spilt vaccine induced a strong IgG antibody response, but induced a weak 
local IgA antibody and cellular response, and provided sub-optimal protection against the 
challenge virus, as viral shedding was reduced but not eliminated.  In the group of pigs 
previously infected then challenged with the swine H3N2 virus, a higher IgA antibody and 
cellular response was observed, and pigs were completely protected against homologous 
challenge.  This work suggests that in order for a vaccine to confer complete protection 
against influenza A virus, both a cellular and humoral immune response must be elicited.  
 
Live-Attenuated Vaccines: 
Live-attenuated vaccines may be able to more closely mimic natural infection, and therefore 
induce a better cell-mediated immune response than inactivated vaccines.  Work done by 
Richt et al92 demonstrated that pigs vaccinated with a modified-live influenza virus vaccine 
made by a deletion in the NS1 gene of an H3N2 virus were completely protected against 
homologous challenge.  The pigs were only partially protected against heterologous 
challenge with an H1N1 influenza virus.   
 There have also been several recent studies examining the use of live-attenuated 
vaccines derived from a combination of several different virus strains for the purpose of 
inducing a more efficacious heterologous protection against various strains of influenza 
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virus, in particular the recently emerging HPAI H5N1 strains.  Desheva et al19 demonstrated 
that a reassortant live-attenuated virus constructed from an H5N2 and a cold-adapted H2N2 
virus could protect mice from a lethal challenge against multiple avian H5N1 virus strains, 
and mice demonstrated a high level of virus-specific mucosal IgA antibodies.  The 
reassortant virus was also formalin inactivated and given to mice intramuscularly, and a 
similar level of protection was observed, however, a stronger serum-neutralizing IgG 
antibody response was observed in the formalin inactivated group, with less of an IgA 
antibody response.  
   
Recombinant Protein/ Viral Vector Vaccines: 
Recombinant protein technology is a relatively new area in vaccine development.  Several 
different types of recombinant protein vaccines have been studied to combat influenza A 
virus infection, such as DNA vaccines in the form of plasmids delivered directly81, plasmids 
in a carrier organism129, proteins expressed in recombinant viruses128, and proteins expressed 
in replicon particles120.   
  
DNA vaccines in the form of plasmids delivered directly into the skin or muscle 
tissue have been widely studied.  Several studies by different research groups have examined 
the use of DNA vaccines against influenza viruses in pigs, with both positive and negative 
results being observed.  Work done by Macklin et al64, demonstrated that pigs vaccinated 
with plasmid DNA expressing influenza HA coated onto gold particles and delivered via 
gene gun to the epidermis or tongue epithelium was able to elicit a protective immune 
response following homologous challenge.  The DNA vaccine did not completely protect 
against challenge, but it reduced the length and severity of viral shedding.   
Work is also being conducted by other researchers to study the use of DNA 
expressing influenza proteins as a primer vaccine followed by a boost using a conventional or 
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recombinant vaccine79.  Heinen et al37 demonstrated that pigs vaccinated with a DNA vaccine 
expressing either influenza M2 protein alone or M2 and nucleoprotein (NP) enhanced disease 
in pigs after challenge, suggesting that antibodies against influenza M2 may not aid in 
protection against influenza disease.  However, studies in mice by Tompkins et al122 suggest 
that the M2 protein may be good target for providing heterologous protection against 
multiple influenza strains, since the M2 protein is more highly conserved than either the HA 
or NA proteins.   
 
Viruses from several different families have been evaluated for their use as 
expression vectors in vaccine studies including pseudorabies virus, a member of 
Herpesviridae121; vesicular stomatitis virus, a member of Rhabdoviridae29; several different 
serotypes of adenovirus, all members of Adenoviridae115; Newcastle disease virus, a member 
of Paramyxoviridae130; and several different alphaviruses, all members of Togaviridae91.  
The following paragraphs will discuss some of the work that has been done regarding the use 
of viral vectors as vaccines against influenza A virus. 
 
Adenoviruses are linear, double stranded DNA viruses that have been widely studied 
in vaccine development as foreign protein expression vehicles.  Originally studied as vectors 
for gene therapy, their ability to elicit a strong host immune response as well as their wide 
tissue tropism made them desirable as vaccine vectors21, 115.  Several different adenovirus 
vectors have been studied for use against a variety of pathogens including human 
immunodeficiency virus (HIV) in nonhuman primates and humans1; Ebola virus and Bacillus 
anthracis in humans1; Yersinia pestis in mice14; and influenza A virus in mice, chickens and 
swine28, 134.   
 Work done by Wesley et al128 demonstrated that pigs vaccinated one time 
intramuscularly with an Ad5 recombinant adenovirus vector expressing influenza A virus 
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(H3N2) hemagglutinin (HA) alone, or expressing HA and nucleoprotein (NP) together, were 
protected against challenge with a closely related H3N2 influenza virus.  Ad5 vectors 
expressing NP alone, however, did not show the same level of protection.  It has also been 
shown that piglets with maternal antibodies against influenza H3N2 could be protected 
against homologous challenge after vaccination with recombinant Ad5 vector expressing 
influenza HA and NP and boosted 3 weeks later with a commercial vaccine (End-FLUence 
2)135. 
One of the major problems associated with human adenovirus vector vaccines is the 
development of a strong neutralizing antibody titer against adenovirus proteins, therefore 
preventing the vector from effectively expressing protein after a single administration111.  
This problem may be due, in part, to the fact that many adenovirus vectors, including those 
tested for animal vaccines, are derived from human adenovirus serotype 5 (Ad5).  In order to 
overcome this problem, researchers are exploring the use of nonhuman adenoviruses as 
vectors, as well as producing chimeric adenovirus vectors from two or more different 
serotypes1, 3, 24, 95.     
 
Newcastle disease virus (NDV) is a single-stranded, negative sense RNA virus that 
encodes six genes130.  Researchers have recently demonstrated that chickens vaccinated with 
a recombinant NDV expressing the HA gene from an avian influenza A virus subtype H5N2 
were protected from a lethal challenge of both NDV and the homologous H5N2 influenza 
virus130.  The vaccine was also able to reduce the level of viral shedding in chickens. 
 
Alphaviruses are single-stranded, positive sense RNA viruses with small genomes 
approximately 12Kb in length91.  Their genome is composed of two open reading frames 
(ORFs) with four nonstructural proteins on the 5’ end of the genome followed by a 26S 
promoter and five structural proteins on the 3’ end91.  In most alphaviruses, the genomic 
 19
RNA packaging signal is located in the coding region of the first or second non-structural 
protein91.  Several different alphaviruses have been engineered for use as virus-like replicon 
particle (VRP) vaccines including: Sindbis virus vector against measles in non-human 
primates84; Semliki Forest virus vector against influenza virus in mice6; and Venezuelan 
equine encephalitis (VEE) virus vector against Lassa and Ebola viruses in guinea pigs89, 
against Simian immunodeficiency virus in macaques18, against human immunodeficiency 
virus in humans67, and against influenza A virus in mice and humans17. 
Virus-like replicon particle vaccines derived from alphaviruses have never been 
tested for use in pigs.  The work described in Chapter 3 of this thesis describe studies that 
evaluate the ability of a VRP vaccine derived from Venezuelan equine encephalitis (VEE) 
virus to elicit an immune response in pigs against a gene of interest, influenza A virus 
hemagglutinin (HA).  Because VRPs had never been tested in pigs, concentrations of VRPs 
used as well as dosing schedule were based upon previous work using VRPs in other animal 
species including mice11, 17, 54-56, guinea pigs89, and nonhuman primates18.  Chapter 4 
describes work done to evaluate the ability of an HA protein lysate vaccine (produced in 
vitro by infecting Vero cells with VRPs expressing the influenza HA gene) to elicit an 
immune response in pigs against the HA protein. 
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CHAPTER 3.  GENERATION OF AN IMMUNE RESPONSE AGAINST 
INFLUENZA HEMAGGLUTININ IN PIGS VACCINATED WITH AN 
ALPHAVIRUS REPLICON 
 
Introduction 
The pork industry has struggled with disease caused by influenza A virus for decades.  Since 
its isolation from pigs in 1930, much work has been done to develop an effective vaccination 
strategy against the virus, but due to its highly mutagenic properties the virus is continuously 
evolving, allowing it to persist as a common respiratory pathogen in swine102.  Current 
vaccination methods are unable to provide protection against all newly emerging virus 
strains, and have been shown to be inadequate at protecting pigs in the presence of 
maternally derived antibody (MDA), therefore new methods of vaccination must be 
explored52, 62, 65, 124.   
Recombinant proteins expressed via viral vectors are currently being evaluated for 
their use in the area of vaccine development.  Due to the simplistic nature of the alphavirus 
genome, several members of this genus have been evaluated for their use as expression 
vectors for vaccination against a variety of pathogens including influenza A virus6, 67, 84.  
Venezuelan equine encephalitis (VEE) virus is a member of the genus alphavirus, family 
Togaviridae.  The genomic structure of VEE consists of single-stranded, positive-sense RNA 
approximately 11.4 kbp in length132.  There are four nonstructural (NS) proteins located at 
the 5’ end which, upon infection in a host cell, are translated into two polyproteins, P123 and 
P123470.  Nonstructural protein 2 (nsP2) acts to cleave these polyproteins into four individual 
NS proteins (nsP1 – nsP4) which make up the viral replication complex that synthesizes both 
full-length copies of the VEE genome as well as subgenomic viral RNAs70.  A 26S 
subgenomic promoter is located after the NS proteins and functions to control expression of 
viral structural proteins (capsid-E3-E2-6K-E1) on the 3’ end of the genome132.    
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 Venezuelan equine encephalitis virus is an arthropod-born pathogen that has been 
known to cause severe disease outbreaks in humans and equine species in Mexico, Central 
America and the northern part of South America since the early 1900s, and it is also known 
to infect other animal species including deer and swine20, 106, 132.  A live attenuated VEE 
vaccine strain, TC-83, was developed in 1961 by passing the virulent Trinidad donkey (TRD) 
strain 83 times in fetal guinea pig heart cells.  The location of the genetic changes that 
provide the attenuation of TC-83 have been found to be located in the 5’-noncoding region 
and E2 gene of the virus51, 132.   
Venezuelan equine encephalitis virus has been shown to target lymphoid tissue, 
specifically dendritic cells during infection, making the virus an ideal candidate for a vaccine 
vector63.  Vectors derived from VEE are of two basic types, double promoter vectors and 
replicon vectors90.  Double promoter vectors are constructed by inserting a second 26S 
promoter either immediately proceeding the original promoter or immediately following the 
E1 gene.  A gene of interest can then be inserted directly downstream of the new promoter, 
allowing the expression of the gene of interest as well as the production of viable VEE 
virions in a host17, 90.  Basic construction of replicons is accomplished by deleting the VEE 
structural genes downstream of the 26S promoter and inserting in their place a gene of 
interest.  During construction of the replicon particles, the structural genes are provided in 
trans, via helper RNAs90.  Replicon particles derived from VEE have been evaluated as 
vaccine vectors in a variety of animal species as well as humans, and clinical trials are 
currently being conducted using VEE replicons against human immunodeficiency virus67. 
Virus-like replicon particles (VRPs) derived from VEE have not yet been tested in 
pigs for their use as vaccine vectors, therefore we performed a series of experiments to 
determine whether or not VRPs would be able in induce an immune response against 
influenza A/Wyoming/03/2003 hemagglutinin (HA) in pigs.  VRPs were provided by 
AlphaVax, Inc. (Research Triangle Park, North Carolina).  VRPs were derived from two 
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different VEE strains, TC-83 described above and V3014, an attenuated VEE strain derived 
from the Trinidad donkey strain, with single amino acid changes in each of the E1 and E2 
genes123.  Strain TC-83 is considered a Biosafety Level 2 agent (BL-2) and VRPs derived 
from this strain may be constructed under BL-2 conditions.  Although V3014 contains 
attenuating mutations, it is still considered a select agent; therefore VRPs derived from this 
strain must be constructed under Biosafety Level (BL-3) conditions.    
 Two separate trials were conducted to evaluate the ability of VRPs to elicit an 
immune response against influenza HA in pigs.  In Trial I, we used VRPs derived from 
V3014 to vaccinate pigs intramuscularly with different concentrations of the VRP.  Our goal 
was to determine if VRPs expressing the hemagglutinin (HA) protein of influenza 
A/Wyoming/03/2003 would be able to elicit an immune response against the HA protein in 
pigs.  Due to unexpected results from Trial I, we were unable to determine if the VRPs could 
elicit an immune response against HA in pigs.  Therefore, in Trial II our first objective was to 
determine if the VRPs could elicit an immune response against HA protein in pigs.  We used 
VRPs derived from either V3014 or TC-83 to vaccinate pigs intramuscularly or intranasally.     
We also wanted to determine if differences could be detected in the immune responses to the 
HA protein in pigs vaccinated with VRPs derived from VEE strain V3014 compared to VEE 
strain TC-83.  Lastly, we evaluated the difference between intramuscular (IM) versus 
intranasal (IN) routes of vaccination.   
 
Materials and Methods     
Construction of Virus-like Replicon Particles: 
Replicons were constructed by removing the structural genes of VEE and inserting in their 
place a spacer region (nonspecific RNA sequence), followed by an internal ribosome entry 
site (IRES), then the influenza A hemagglutinin (HA) gene of A/Wyoming/03/2003 
immediately downstream of the 26S promoter46.  Replicons used in the negative control pigs 
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were constructed in the same manner, but the Gag gene of human immunodeficiency virus 
(HIV) was inserted after the IRES in place of the influenza HA gene.  Many different viruses 
encode IRES elements in their genomes in order to selectively recruit host cell 40S 
ribosomes to translate viral mRNA into proteins99.  By inserting the IRES element upstream 
of the influenza HA gene, production of HA protein in host cells could be selectively 
increased, with the goal of eliciting a stronger immune response to the HA protein in pigs46.  
During assembly of VRPs, VEE structural genes were provided in trans via two separate 
helper plasmids, one containing the capsid gene of VEE and the other containing the E3-E2-
6K-E1 genes of VEE in order to decrease the likelihood of recombination between viral 
genes resulting in the production of virulent virus particles90.  In order to evaluate the safety 
of replicons derived from V3014, newly formed replicons were tested by cytopathic effect 
(CPE) assay for the presence of any live VEE virus caused by recombination between 
replicon and helper plasmid genes.  In the CPE assay, newly constructed V3014 VRPs are 
passaged two times in Vero cells, then inspected under a light microscope for CPE caused by 
live VEE virus.  If no CPE is observed, then VRPs can be released from BL-3 containment 
and used in humans and animals.  This assay has been approved by the Food and Drug 
Administration. 
 Once constructed, infectious titer of the VRPs was determined by indirect fluorescent 
antibody (IFA) assay.  Serial dilutions of VRP were incubated with Vero cells for 30 to 60 
minutes at 37ºC, 5%CO2, and then cells were incubated for 18 to 20 hours at 37ºC, 5%CO2.  
Following incubation, cells were washed, fixed, and stained with an antigen-specific primary 
antibody followed by a FITC-conjugated secondary antibody.  Cells were observed using 
ultraviolet fluorescence microscopy (Nikon Eclipse TE300) and antigen-positive cells were 
counted to determine the titer of VRPs expressed as infectious units (IU)/mL.   
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Trial I Animals: 
Twenty-four 3-week-old pigs arrived to ISU on Day -7 from a herd believed to be swine 
influenza virus (SIV) negative based on prior serology (Northwood, Randy Witt).  Sow 
number and date of birth were recorded prior to the pigs being taken into the Biosafety 
Level-2 (BL2) Livestock Infectious Disease Isolation Facility (LIDIF) and weighed.  Pigs 
were stratified by sow and weight and randomized using SAS software into 6 groups of 4 
pigs per group. The three negative control (Gag) groups were housed in a room separate from 
the three HA vaccinate groups (see Table 1).  Pigs were housed by group on elevated decks 
with no nose to nose contact with other groups within a room.  Blood was collected 4 days 
prior to immunization (Day -4) and submitted to the Iowa State University Veterinary 
Diagnostic Lab for hemagglutination-inhibition (HI) testing using SIV H1N1 (99) and H3N2.  
Nasopharyngeal swabs were collected on Day 0 and tested for influenza antigen using the 
Directigen Flu A test kit (Becton Dickinson).   The strain of human influenza used in the 
vaccine (A/Wyoming/03/2003) was not available pre-immunization for HI assay and thus 
pre-bleed serum was archived to be tested at a later date. 
 
Trial I Immunizations: 
Virus-like replicon particles (VRPs) derived from Venezuelan equine encephalitis virus were 
sent from AlphaVax Inc. (Research Triangle Park, North Carolina) to ISU on dry ice and 
immediately placed at -80ºC until used.  V3014 HA-VRP expressed the hemagglutinin (HA) 
gene from human influenza virus A/Wyoming/03/2003 (H3N2).  V3014 Gag-VRP expressed 
the gag gene from HIV and was used as a negative control.  Vaccine doses were prepared by 
diluting the stock VRP in filter sterilized PBS (pH 7.2, without Mg2+ and Ca2+, Sigma, St. 
Louis, MO) with 1% swine serum (obtained from pig #6 on Day -4 of this study). 
Formulations were held on ice and administered intramuscularly to pigs for immunizations 1 
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and 2 and either intramuscularly (2 of 4 pigs per group) or intradermally (2 of 4 pigs per 
group) for immunization 3 to the pigs within 1 hour.  
The doses of VRPs given are shown in Table 1. Pigs were immunized on Days 0, 28, 
and 57.  Groups received either 105, 106, or 107 infectious units (IU) for the first and second 
immunizations.  However, all pigs received 108 IU of the appropriate VRP on Day 57.  
Following the first immunization, blood was collected on days 7, 14, 21, 28, 35, 42, 56, 64, 
and 77.  Blood was centrifuged for 25 minutes at 1,200 x g, 4ºC to collect serum.  Serum was 
frozen at -20ºC for storage.  
 
Trial I Necropsy: 
Pigs were euthanized on Day 77 via electrocution in accordance with AVMA suggested 
guidelines.  Blood was collected in SST Plus blood collection tubes, and injection sites 
inspected for lesions.  Serum was collected as described above and frozen at -20ºC for 
storage. 
 
 
Table 1: Experimental design for Trial I. 
Group # 
(4 pigs/group) 
VRP 
Treatment 
Routea Dose on Days 
0 and 28 (IU) 
Dose on Day 
57 (IU) 
1 V3014 HA IM/ID 105 108
2 V3014 HA IM/ID 106 108
3 V3014 HA IM/ID 107 108
4 V3014 Gag IM/ID 105 108
5 V3014 Gag IM/ID 106 108
6 V3014 Gag IM/ID 107 108
a All pigs were vaccinated intramuscularly (IM) in the ham on Days 0 and 28.     
  2 of 4 pigs in each group were vaccinated intradermally (ID), and the other 2   
  were vaccinated intramuscularly on Day 57.  
 
 
Trial II Animals: 
Thirty 3-week-old pigs arrived on Day -7 from a different herd than used in Trial I (Ledger 
Swine Farms, Gary Ledger) in an effort to find pigs that were free of maternal antibody 
against A/Wyoming/03/2003.  Pigs were weighed and then randomized using Research 
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Randomizer software into 6 groups of 5 pigs per group. Groups 1, 2, and 6 were housed in 
one room and groups 3, 4 and 5 in another (see Table 2).  Pigs in each pen had no nose to 
nose contact with pigs in the other two pens.  Blood was collected 7 days prior to 
immunization (Day -7) and tested by hemagglutination-inhibition assay for antibodies against 
A/Wyoming/03/2003. 
 
Trial II Immunizations: 
VRPs were obtained from the same source as in Trial I (AlphaVax Inc.). Gag-VRP expressed 
the Gag gene from HIV and was used as a negative control, as in Trial I.  V3014 HA-VRP 
and TC-83 HA-VRP both expressed the hemagglutinin (HA) gene from human influenza 
virus A/Wyoming/03/2003.     
Vaccine doses were prepared by diluting the stock VRP in filter sterilized PBS (pH 
7.2, without Mg2+ and Ca2+, Sigma, St. Louis, MO) with 1% swine serum (obtained from pig 
#29 on Day -7 of this study) and formulations were held on ice and administered to pigs 
within 1 hour.  The doses of VRPs given are shown in Table 2.  Pigs were immunized on 
Days 0 and 28.  Nine of 30 pigs were also immunized again on Day 53 (see Table 2).  Groups 
received 109 IU for all immunizations.  Following the first immunization, blood was collected 
in SST Plus blood collection tubes (Becton Dickinson, Franklin Lakes, NJ) on days 14, 28, 
42, and 52.  Blood was centrifuged for 25 minutes at 1,200 x g, 4ºC to collect serum.  Serum 
was frozen at -20ºC for storage. 
 
Trial II Necropsy: 
On Day 63, pigs were euthanized using intravenous Sleepaway (Fort Dodge Animal Health, 
Fort Dodge, IA) and weighed, followed by exsanguination.  Blood was collected in SST Plus 
blood collection tubes.  Serum was collected as stated above and frozen at -20ºC for storage. 
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Table 2: Experimental design for Trial II. 
Group # 
(5 pigs/group) 
VRP 
Treatment 
Routea Dose on Days 0 
and 28 (IU) 
Dose on Day 
57 IU) 
1 TC-83 HA IM 109 none 
2 TC-83 HA IN/IM 109 *109
3 V3014 HA IM 109 none 
4 V3014 HA IN/IM 109 *109
5 V3014 Gag IM 109 none 
6 V3014 Gag IN/IM 109 *109
a Pigs were vaccinated either intramuscularly (IM) in the ham or intranasally (IN). 
* Three of 5 pigs in each of groups 2, 4, and 6 were vaccinated intramuscularly  
   on Day 57.  The remaining pigs were not vaccinated after Day 28. 
 
 
Virus Propagation for Hemagglutination Inhibition Assay: 
Influenza virus A/Wyoming/03/2003 (H3N2) was obtained from Dr. Sasha Alexander 
(Centers for Disease Control, Atlanta, GA).  Embryonated chicken eggs, approximately 11 
days old, were purchased from the National Veterinary Services Laboratories (Ames, Iowa).  
Eggs were candled and marked along the air sac.  An engraver was used to make a hole over 
the air sac of the egg, just large enough to insert a tuberculin syringe needle into the egg.  A 
tuberculin syringe was used to inject 100µL of A/Wyoming virus diluted to 103 infectious 
particles/mL into the chorioallantoic cavity of the egg.  The eggs were sealed and incubated 
at 37ºC without CO2.  Embryos were checked daily, and any that died within 24 hours were 
discarded.  After 2-3 days, eggs were chilled for at least 4 hours at 4ºC, then virus was 
aseptically harvested by opening the shell over the air sac and pipetting out the clear allantoic 
fluid containing the virus.  The fluid was pooled and centrifuged for 15 minutes at 750 x g, 
4ºC.  Supernatant containing the virus was collected and stored at -80ºC. 
 
Hemagglutination-Inhibition Assay: 
The hemagglutination inhibition (HI) assay was performed as previously described83.  
Briefly, turkey erythrocytes diluted 1:1 in Alsever’s solution were purchased from the 
National Veterinary Services Laboratories (Ames, Iowa).  Upon arrival, turkey erythrocytes 
were washed three times in sterile PBS (pH 7.4) by adding approximately 30 mL PBS to 15 
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mL erythrocyte solution, gently inverting to mix, then centrifuging for 10 minutes at ~370 x 
g, 4ºC.  After the third wash, a 0.4% erythrocyte solution was made and stored for a 
maximum of seven days at 4ºC for use in the HI assay.  The remaining erythrocyte pellet was 
stored for a maximum of seven days at 4ºC for use in the treatment of serum. 
Serum collected from pigs was diluted 1:3 in receptor destroying enzyme (DENKA, 
Seiken) and allowed to incubate for 18-20 hours at 37ºC.  Serum samples were then heat 
inactivated for 30 minutes at 56ºC, allowed to cool to room temperature, and then diluted to a 
final concentration of 1:9 in sterile PBS (pH 7.4).  Washed, packed turkey erythrocytes were 
added to each sample at a concentration of 1:20.  Serum plus erythrocytes were mixed by 
pipetting, and then allowed to incubate at room temperature for 30 minutes.  The serum 
mixture was then centrifuged for five minutes at approximately 12,000 x g on a table top 
centrifuge.  Serum was pipetted off of the erythrocyte pellet into clean microcentrifuge tubes 
and serum samples were stored at 4ºC for use within the next 5 days, or placed at -20ºC for 
extended storage. 
  Hemagglutination was performed using 0.4% turkey erythrocytes and four 
hemagglutinating units of influenza virus A/Wyoming/03/2003.  A titer ≥ 1:40 was 
considered positive. 
 
Hemagglutinin ELISA: 
The hemagglutinin (HA) ELISA was preformed at AlphaVax, Inc. (Research Triangle Park, 
NC).  Serum samples collected from pigs were sent on ice to AlphaVax.  To measure 
antigen-specific humoral immune responses to HA in animals immunized with the HA-VRP 
vaccine, purified recombinant HA antigen derived from A/Wyoming/03/2003 (Protein 
Sciences Inc) was used in an ELISA.  Briefly, 96-well Maxisorp ELISA plates (Nunc, 
Naperville, IL) were coated with 50 ng/well of recombinant HA protein in carbonate buffer.  
After overnight incubation at 4ºC, unbound antigen was discarded and each well was 
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incubated for 1 hr with blocking buffer (PBS containing 3% bovine serum albumin) at room 
temperature.  After washing 6 times with PBS, test sera that were serially 2-fold diluted in 
diluent buffer (PBS with 1% BSA and 0.05% Tween-20) were added in triplicate to antigen-
coated wells.  Antigen-coated wells that received no serum served as background controls.  
Plates were incubated for 1 hour at room temperature, and then rinsed six times with PBS.  
Alkaline phosphatase-conjugated anti-pig IgG (whole molecule) antibody (Sigma, St. Louis, 
MO) was added to each well and incubated for 1 hr at room temperature.  Wells were rinsed 
again six times with PBS before addition of alkaline phosphatase substrate and chromogen.  
Samples were read at 405 nm on a PowerWave 200 Microplate Scanning Spectrophotometer 
(BioTek Instruments, Winooski, VT).  Endpoint titers were calculated using SOFTmax 
(Molecular Device Corp., Menlo Park, CA), and mean antibody titers were determined for 
each group.  Titers are reported as the reciprocal of the serum dilution at which the A405 is 
≥ 0.2. 
 
Virus-like Replicon Particle Neutralization Assay: 
The virus-like replicon particle (VRP) neutralization assay was preformed at AlphaVax, Inc. 
(Research Triangle Park, NC) to measure neutralizing antibody responses in the pigs against 
the VRPs.  Serum samples were heat inactivated by incubation at 56°C for 30 minutes.  Each 
serum sample was diluted 1:10 in EMEM.  The diluted serum samples were then further 
serially diluted in 2 fold increments.  VRP expressing green fluorescent protein (GFP-VRP) 
were added to each dilution and incubated at 4°C overnight.   
Vero cells grown in 96 well tissue culture plates (~4 x 104 / cells well) were incubated 
for 16 – 18 hours, then media was removed from each well and 50µl of the serum/VRP 
samples was transferred to each well of the 96 well plate.  The serum/VRP was incubated on 
the cells for 1 hr at 37°C, the samples were removed from the cells and 0.1mL of fresh 
media/well replaced.  The plates were incubated overnight at 37°C.  After overnight 
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incubation the media was replaced with 0.1mL of PBS.  The reduction in GFP positive cells 
(compared to control serum treated VRP) was analyzed using ultraviolet fluorescence 
microscopy (Nikon Eclipse TE300).  The VRP neutralizing antibody titer was expressed as 
the reciprocal end point dilution at which 80% of the GFP-VRPs were neutralized. 
 
Statistics: 
Tukey-Kramer HSD analysis was used to compare HI titers of pigs by group for each day 
that blood was collected.  In order to allow for log transformation of titers with a value of 0, 
an arbitrary value of 0.5 was added to all HI titers, and then titers were log10 transformed, and 
analysis was preformed on log transformed data.  Analysis was conducted using the 
statistical software JMP 6.0.0 (SAS Institute, Cary, NC). 
 
Results 
Trial I: 
All 24 pigs in Trial I tested negative by hemagglutination-inhibition (HI) assay for antibody 
against SIV H3N2 on Day -4 (data not shown).  One pig of 24 (pig 16) was suspect positive 
by HI for antibody against SIV H1N1 (99) with a titer of 40 (data not shown).  The other 23 
pigs tested negative for antibody against SIV H1N1 (99).  All 24 pigs tested negative for the 
presence of influenza A antigen by the Directigen Flu A test kit (Becton Dickinson) (data not 
shown). 
In Trial I, 23 of 24 pigs had a maternally derived antibody (MDA) HI titer of 20 or 
greater against influenza A/Wyoming/03/2003 on Day -4, while one pig (pig 24) had a 
maternal antibody titer of 0 by HI assay on Day -4 (see Table 3).  Geometric mean titers were 
determined for each group (see Figure 1).  There was no significant difference in HI titers 
between any of the groups on any of the days.  Pig 24 did appear to respond to vaccination, 
and had an HI titer of 320 by Day 64 of the trial (data not shown), but data from one pig does 
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not provide enough evidence to make any specific conclusions about the ability of VRPs to 
elicit any immune response in pigs against HA.  The data shown from Trial I demonstrated 
the need to find a swine herd that did not have antibodies to influenza A/Wyoming/03/2003.  
 
 
Table 3: Trial 1- Hemagglutinin-Inhibition antibody titer of pigs on Day -4.      
Group # Pig # Sow #a HI titer 
Day -4b
Group # 
 
Pig # Sow #a HI titer 
Day -4b
1 6 24 20 4 1 24 20 
V3014  10 97551 80 V3014  8 24 20 
HA 14 91 40 Gag 11 97551 80 
105 22 93 80 105 18 91 80 
2 3 24 20 5 5 24 20 
V3014  4 24 20 V3014  7 24 20 
HA 13 97551 160 Gag 17 91 80 
106 20 93 80 106 21 93 80 
3 9 24 20 6 2 24 20 
V3014  12 97551 160 V3014  15 91 80 
HA 16 91 80 Gag 19 91 80 
107 24 93 0 107 23 93 80 
a Pigs from Trial I came from 4 different sows (sow 24, 91, 93, and 97551)   
b Titers represent maternally derived antibody.  Pig 24 was the only pig without 
maternally derived antibody on Day -4 
 
 
 
Figure 1: Trial I - Hemagglutination-Inhibition geometric mean titers (GMT) of 
pigs by group.  Group 1: HA 10^5, Group 2: HA 10^6, Group 3: HA 10^7, 
Group 4: Gag 10^5, Group 5: Gag 10^6, Group 6: Gag 10^7.  GMT were 
calculated by taking the log10(HI titers + 0.5) of pigs on all days, then calculating 
the mean of the logs.  Error bars represent 95% confidence interval.  
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Trial II: 
In Trial II, 9 of 30 pigs had an initial MDA HI titer of 160 or greater, while the other 21 pigs 
tested negative (titers = 0) for MDA against A/Wyoming by HI assay (see Table 4).  Figure 2 
shows the geometric mean titers of pigs by group.  On Days -7, 14, 28, 42, and 52 there was 
no significant difference in HI titers between any of the groups.  On Day 63, pigs vaccinated 
IM with either TC-83 HA or V3014 HA (Groups 1 and 3) had significantly higher HI 
antibody titers than pigs vaccinated IN with either TC-83 or V3014 (Groups 2 and 4) and 
pigs vaccinated either IM or IN with 3014 Gag (negative controls, Groups 5 and 6).  On day 
63, there was no significant difference in HI titers between pigs in Group 1 versus Group 3, 
demonstrating that VRPs derived from either TC-83 or V3014 work equally well at eliciting 
an immune response against HA in pigs.  On Day 63 there were no significant differences 
between Groups 2, 4, 5, and 6, demonstrating that the IN route of vaccination was less 
efficient than the IM route at eliciting a serum antibody response against HA in the pigs.     
 
ELISA data is shown in Table 5 and Figures 3-6.  Six of 20 pigs in groups vaccinated 
with HA-VRPs (groups 1-4) had MDA against A/Wyoming.  Table 5 shows the OD405 values 
for pigs vaccinated with HA-VRPs on Days -7, 14, and 28.  The 6 pigs with MDA had OD405 
values > 0.5 on Day -7, while pigs without MDA had OD405 values < 0.1 on Day -7.  By Day 
14, the six pigs with MDA had lower OD405 values, showing decay in their maternal 
antibodies, but pigs without MDA started to show an increase in OD405 values, indicating a 
possible response to vaccination.  By Day 28, OD405 values for pigs without MDA had 
increased further, with most pigs having an OD405 value > 0.1, therefore serum collected 
from pigs on Day 14 was used as baseline or “negative” serum to calculate ELISA titers on 
Days 42, 52, and 63.  Titers of all pigs in groups 1-4 may be considered < 40 on Days -7, 14, 
and 28.  HA ELISA was not run on serum from pigs vaccinated with Gag-VRPs (Groups 5 
and 6).  
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 Figures 3 and 4 show HA ELISA titers of pigs vaccinated either IN or IM with 109 IU 
of TC-83 HA-VRP.  Figures 5 and 6 show HA ELISA titers of pigs vaccinated either IN or 
IM with 109 IU of V3014 HA-VRP.  Pigs vaccinated IN (Figures 3 and 5) had lower ELISA 
titers than pigs vaccinated IM (Figures 4 and 6).  Titers for pigs vaccinated IM with either 
TC-83 or V3014 HA-VRP (Figures 4 and 6) were comparable between these two groups. 
 
Table 6 shows VRP neutralization titers for pigs in on Days -7, 14, and 28.  Pigs in 
groups 1, 2, 4, and 6 had low or no levels of antibodies against the VRP vectors on all 3 days, 
while pigs in groups 3 and 5 had titers of ≤ 1280 by day 28.  Pigs in group 3 were vaccinated 
intramuscularly in the ham with 109 IU of V3014 HA-VRP, while pigs in group 5 were 
vaccinated intramuscularly in the ham with 109 IU of Gag-VRP. 
 
 
Table 4: Trial II - Hemagglutination-Inhibition titers on Day -7. Nine 
of 30 pigs were positive by HI for the presence of maternally derived 
antibody. 
Group # Pig # HI Titer 
Day -7 
Group # Pig # HI Titer 
Day -7 
1 2 160 4 8 0 
TC-83 9 320 V3014 12 0 
IM 14 0 IN 17 160 
 18 320  22 0 
 29 0  26 0 
2 4 0 5 3 320 
TC-83 11 320 Gag 7 320 
IN 20 0 (Negative 10 0 
 23 0 Control) 16 0 
 28 0 IM 27 0 
3 1 0 6 15 0 
V3014 5 160 Gag 19 0 
IM 6 0 (Negative 24 320 
 13 0 Control) 25 0 
 21 0 IN 30 0 
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Figure 2: Trial II - Hemagglutination-Inhibition geometric mean titers (GMT) of 
pigs by group.  Group 1: TC-83 IM, Group 2: TC-83 IN, Group 3: V3014 IM, 
Group 4: V3014 IN, Group 5: Gag IM, Group 6: Gag IN.  GMT were calculated 
by taking the log10(HI titers + 0.5) of pigs on all days, then calculating the mean 
of the logs.  Error bars represent 95% confidence interval.  
 
 
Table 5: Trial 2 ELISA Optical Density values for Days -7, 14 and 28.   
ELISA OD405 at 1:40 
dilution 
ELISA OD405 at 1:40 
dilution 
Group # Pig # 
Day -7  Day 14 Day 28 
Group # 
 
Pig # 
Day -7  Day 14 Day 28 
1 2* 1.14 0.462 0.324 3 1 0.094 0.307 0.460 
 9* 1.27 0.707 0.485  5* 1.240 0.597 0.405 
 14 0.082 0.163 0.267  6 0.087 0.105 0.187 
 18* 1.20 0.653 0.448  13 0.092 0.111 0.159 
 29 0.081 0.101 0.133  21 0.086 0.085 0.141 
2 4 0.088 0.095 0.111 4 8 0.095 0.091 0.118 
 11* 1.17 0.453 0.380  12 0.093 0.082 0.098 
 20 0.095 0.080 0.095  17* 0.514 0.181 0.141 
 23 0.090 0.080 0.109  22 0.086 0.094 0.102 
 28 0.091 0.081 0.100  26 0.080 0.084 0.115 
*indicates pigs with maternal antibody against A/Wyoming.   
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Figure 3: HA ELISA titers for Trial 2, group 2, pigs vaccinated 
intranasally with 109 IU of TC-83 HA-VRP on Days 0 and 28.  Pigs 4, 
11 and 20 were vaccinated for a third time intramuscularly in the ham on 
Day 53 with 109 IU of TC-83 HA-VRP. ELISA titers are defined as the 
reciprocal of the highest dilution of serum for which the optical density 
was ≥ 2 times the optical density of serum diluted 1:40 from Day 14. 
*denotes pig(s) with maternal antibody against A/Wyoming. 
 
 
 
Figure 4: HA ELISA titers for Trial 2, group 1, pigs vaccinated 
intramuscularly in the ham with 109 IU of TC-83 HA-VRP on Days 0 
and 28.  No pigs in group 1 were vaccinated after Day 28. ELISA titers 
are defined as the reciprocal of the highest dilution of serum for which 
the optical density was ≥ 2 times the optical density of serum diluted 
1:40 from Day 14. *denotes pig(s) with maternal antibody against 
A/Wyoming. 
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Figure 5: HA ELISA titers for Trial 2, group 4, pigs vaccinated 
intranasally with 109 IU of V3014 HA-VRP on Days 0 and 28.  Pigs 8, 
12 and 17 were vaccinated for a third time intramuscularly in the ham on 
Day 53 with 109 IU of V3014 HA-VRP. ELISA titers are defined as the 
reciprocal of the highest dilution of serum for which the optical density 
was ≥ 2 times the optical density of serum diluted 1:40 from Day 14. 
*denotes pig(s) with maternal antibody against A/Wyoming. 
 
 
 
Figure 6: HA ELISA titers for Trial 2, group 3, pigs vaccinated 
intramuscularly in the ham with 109 IU of V3014 HA-VRP on Days 0 
and 28.  No pigs in group 3 were vaccinated after Day 28. ELISA titers 
are defined as the reciprocal of the highest dilution of serum for which 
the optical density was ≥ 2 times the optical density of serum diluted 
1:40 from Day 14. *denotes pig(s) with maternal antibody against 
A/Wyoming. 
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Table 6: Trial 2 VRP neutralization data.  
VRP Neutralization Titer VRP Neutralization Titer Group # Pig # 
Day -7 Day 14 Day 28 
Group # 
 
Pig # 
Day -7 Day 14 Day 28 
1 2 < 20 40 < 20 4 8 < 20 < 20 < 20 
 9 < 20 20 < 20  12 < 20 < 20 < 20 
 14 < 20 < 20 < 20  17 < 20 < 20 < 20 
 18 < 20 40 < 20  22 < 20 < 20 < 20 
 29 < 20 20 < 20  26 < 20 < 20 < 20 
2 4 < 20 < 20 < 20 5 3 < 20 160 320 
 11 < 20 20 < 20  7 < 20 160 160 
 20 < 20 < 20 < 20  10 < 20 1280 1280 
 23 < 20 < 20 < 20  16 < 20 40 320 
 28 < 20 < 20 < 20  27 < 20 40 80 
3 1 < 20 320 640 6 15 < 20 < 20 < 20 
 5 < 20 >1280* 1280  19 < 20 < 20 < 20 
 6 < 20 40 160  24 < 20 < 20 < 20 
 13 < 20 160 640  25 < 20 < 20 - 
 21 < 20 160 320  30 < 20 < 20 < 20 
* value for pig 5 on Day 14 was not determined beyond 1280.  Pig 25 was euthanized prior to Day 28  
  due to complications unrelated to the study. 
 
 
Discussion 
In Trial I our objective was to determine if VRPs expressing the hemagglutinin (HA) protein 
of influenza A/Wyoming/03/2003 would be able to elicit an immune response against the HA 
protein in pigs.  Because VRPs had never been tested in pigs, concentrations of VRPs used as 
well as dosing schedule were based upon previous work using VRPs in other animal species 
including mice11, 17, 54-56, guinea pigs89, and nonhuman primates18.  Due to the unexpected 
fact that only one pig of 24 did not have a MDA titer against A/Wyoming (pig 24) and this 
pig had the highest HI titer at necropsy (data not shown), further work was needed to 
determine if the response seen in this one pig was representative of a larger portion of the 
swine population.  Also, serum from pig 6 on Day -4 was used in the VRP vaccine 
formulations at a concentration of 1%.  Pig 6 had an HI antibody titer of 20 on Day -4 due to 
the presence of MDA, but this was not known until after the termination of the study.  Due to 
the low concentration of serum in the vaccine formulation, it is not likely that this caused 
major changes in the HI titers of pigs in Trial I, but it is possible that the antibody against 
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influenza HA from this serum could have negatively impacted vaccination of pigs in this 
trial.  Maternally derived antibodies have previously been shown to be inefficient at 
protecting piglets from experimental influenza infection against both homologous and 
heterologous virus strains52, 61.  It has also been shown that MDA may interfere with the 
ability of some vaccines to elicit a protective immune response against influenza virus52, 52.   
 
In Trial II, our objectives were threefold.  First, we wanted to determine if the results 
seen in Trial I for pig 24 (no maternal antibody against A/Wyoming) could be reproduced to 
demonstrate the capability of VRPs to elicit an immune response against influenza HA in 
pigs.  Secondly, we wanted to determine if a difference could be detected in immune 
response to the HA protein between pigs vaccinated with VRPs derived from V3014 versus 
TC-83.  Thirdly, we wanted to evaluate the difference between intramuscular (IM) versus 
intranasal (IN) routes of vaccination.  Based upon hemagglutination-inhibition (HI) and 
ELISA titers, we demonstrated that VRPs derived from VEE are able to elicit an immune 
response in pigs.  Based upon our data, the intramuscular (IM) route of vaccination appeared 
more effective at eliciting a serum antibody response in pigs against HA than the intranasal 
(IN) route when vaccinating pigs with VRPs.  We also showed that VRPs derived from either 
TC-83 or V3014 were equally efficient at expressing the HA protein in vivo, as no significant 
difference was observed in immune responses between pigs vaccinated with either of these 
VRPs.  Because V3014 is considered a select agent, VRPs derived from this VEE virus strain 
must be constructed under Biosafety-level 3 conditions.  Replicons constructed from TC-83 
may be constructed under Biosafety-level 2 conditions; therefore the use of TC-83 to 
construct VRPs is desirable in that production costs are less for VRPs derived from TC-83 
than for VRPs derived from V3014. 
Although the sample size of pigs is not large enough to make any specific 
conclusions, it is interesting to note that most pigs in Trial II with an initial MDA titer against 
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A/Wyoming and vaccinated either IM or IN with HA-VRPs maintained HI titers of ≥ 40 
throughout most or all of the study (data not shown).  Pigs in the negative control Gag-VRP 
groups that had an initial MDA titer against A/Wyoming all reached HI titers of ≤ 20 by Day 
52.  Work done with an adenovirus vaccine vector has shown promise as an effective vaccine 
against influenza in the presence of MDA.  It was shown that piglets with MDA against 
influenza H3N2 could be protected against homologous challenge after vaccination with 
recombinant Ad5 vector expressing influenza HA and NP and boosted 3 weeks later with a 
commercial vaccine (End-FLUence 2)135.  It is possible that VRP vaccines may be able to 
provide similar protection in the presence of MDA.  Further work is needed to optimize 
vaccination dosing and schedule of VRP administration in order to determine the maximum 
response that can be achieved in pigs vaccinated with VRPs.  More work is also needed to 
determine whether or not VRPs can elicit an immune response to HA in the presence of 
MDA, and whether or not the immune response elicited by VRPs is protective against virus 
challenge. 
One problem faced by some viral vector vaccines is that the host develops an immune 
response against the vector itself, reducing the effectiveness of the vector to express its gene 
of interest.  An example of this is human adenovirus vector vaccines, in which the 
development of a strong neutralizing antibody titer against adenovirus proteins has been 
shown to prevent the vector from effectively expressing protein after a single 
administration111.  In Trial I, all pigs had a VRP neutralization titer of ≥ 20 by Day 64 (data 
not shown).  Pig 24 had a VRP neutralization titer of >1280, yet still responded to VRP with 
an HI titer of 320 by necropsy (Day 77).  In Trial II, only pigs in groups 3 and 5 had VRP 
neutralization titers of ≥ 20 by Day 28.  More work is needed to determine whether VRP 
neutralization titers would prevent the use of another VRP vaccine from efficiently 
expressing its gene of interest in pigs.  One way to circumvent this potential problem is to 
simultaneously vaccinate pigs with multiple VRPs each expressing one gene of interest or 
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one VRP expressing several different genes of interest to protect against a broad range of 
pathogens.  Work done in mice has shown that replicons derived from Venezuelan equine 
encephalitis virus expressing genes from either Marburg virus, Bacillus anthracis, or 
Clostridium botulinum administered simultaneously were able to provide protection against 
challenge with Clostridium botulinum, demonstrating that VRPs expressing different proteins 
administered simultaneously do not inhibit the effectiveness of one another55.  Further work 
is needed to determine if VRPs administered simultaneously can protect against challenge 
with multiple infectious agents.     
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CHAPTER 4.  IMMUNOGENECITY IN PIGS OF INFLUENZA HEMAGGLUTININ 
PROTEIN DERIVED FROM AN ALPHAVIRUS REPLICON 
 
Introduction 
Improved methods of vaccination against influenza A virus in swine are needed to prevent 
economic loss to the swine industry due to increased length of time needed for pigs to reach 
market weight80.  Influenza virus hemagglutinin (HA) is one of two major viral surface 
proteins, and antibody against the HA protein has been shown to be protective against virus 
challenge93, 113.  Recently, recombinant protein technology has allowed for the development 
and mass production of recombinant HA (rHA) protein for use in vaccines against influenza 
virus76.  Work done in mice has shown that rHA and neuraminidase (NA) proteins produced 
via baculovirus vectors were able to elicit a protective immune response against influenza 
challenge45 and work done in chickens demonstrated that rHA protein vaccine was able to 
protect chickens from challenge with H5 and H7 influenza subtypes15.  In clinical trials, the 
use of rHA produced via baculovirus expression vectors in insect cell lines has shown much 
promise for commercialization as a vaccine against influenza infection66.   
 We wanted to evaluate the ability of rHA protein produced in vitro in Vero cells from 
alphavirus virus-like replicon particles (VRPs) to elicit an immune response in pigs.  One 
trial was conducted in which rHA protein was used to vaccinate pigs intramuscularly either 
alone or with an adjuvant.  Two different adjuvants were tested, Emulsigen-D (MVP 
Laboratories, Omaha, NE) and VRPs derived from Venezuelan equine encephalitis (VEE) 
virus.  Previous work in mice demonstrated that when VRPs expressing an irrelevant gene 
(green fluorescent protein) were administered with an inactivated influenza virus, they had 
the ability to elicit a strong systemic and mucosal response to the influenza HA protein, even 
when administered at a non-mucosal site120.  Therefore, these two adjuvants were each 
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evaluated for their ability to help stimulate a strong immune response against the HA protein 
in pigs.   
Recombinant HA was produced from VRPs derived from Venezuelan equine 
encephalitis virus.  We also challenged pigs with live A/Wyoming/03/2003 influenza virus in 
order to determine if an immune response elicited by replicon-derived HA protein would 
protect pigs from virus challenge. 
 
Materials and Methods 
Vaccine Preparation - HA and PRRS Protein Lysate: 
The protocol for preparation of HA and PRRS lysate was obtained from AlphaVax Inc. 
(Research Triangle Park, NC).  African green monkey kidney (Vero) cells obtained from 
American Type Culture Collection were propagated in growth media (DMEM supplemented 
with 4% fetal bovine serum and 0.2% gentamicin).  Cells were allowed to grow for 
approximately 18 - 20 hours in 75 cm2 cell culture flasks, and then cells in one flask were 
counted using a hemocytometer.  First, growth media was removed and cells were rinsed 
with 2-3mL trypsin.  Cells were then incubated with 5mL trypsin for approximately 5-10 
minutes at 37ºC until cells detached from flask.  Total volume of the cell solution was 
measured, then 100µL of cells was mixed with 400µL of Trypan Blue stain.  Cells were 
pipetted into a hemocytometer, and cells were counted under a light microscope.  Total cells 
per mL were determined according to the following equation: 
 
Total cells/mL = (total cell count/ 5) x (1/ dilution of cells in Trypan Blue) x 104
 
Total number of cells per flask was then calculated.  VRPs expressing either the 
hemagglutinin (HA) protein from A/Wyoming/03/2003 or the glycoprotein 5 (gp5) from 
porcine respiratory and reproductive syndrome (PRRS) virus (used as negative control 
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protein) were then diluted appropriately in growth media to be used to infect Vero cells at a 
multiplicity of infection (MOI) of 5.  VRPs in growth media were added to cells and allowed 
to incubate for 1 hour at 37ºC, 5% CO2.  Flasks containing VRP infected cells were gently 
swirled every 15 minutes.  After 1 hour, VRPs were pipetted off of the cells, and 40 mL 
growth media was added to each flask.  Cells were incubated for 18 hours at 37ºC, 5% CO2.  
After 18 hours, growth media was removed from the flasks, cells were washed one time with 
sterile PBS, pH 7.2, then 25mL of lysis buffer (10mM Tris-HCl pH 7.4, 1mM EDTA, 0.25 
mM NaCl, 1% Triton X-100, and 1tablet/ 50mL Complete EDTA-Free Protease Inhibitor 
Cocktail, Roche, Basel, Switzerland) was added to each 75 cm2 cell culture flask.  Flasks 
were gently rocked for 7 – 10 minutes at room temperature to lyse cells.  Cellular suspension 
was then pipetted from each flask and centrifuged for 25 minutes at ~4,500 x g, 4ºC.  
Supernatant was collected and tested via western blot for the presence of the desired protein.  
Supernatant was then used to vaccinate pigs in Trial 3, above, on Days 21 and 49.   
 
Animals:  
Thirty 3-week-old pigs arrived at ISU on Day -7 from a herd believed to be negative for 
influenza A/Wyoming/03/2003 (Ledger Swine Farms, Gary Ledger).  Sow number was 
recorded.  Pigs were randomized using Research Randomizer software into 6 groups of 5 
pigs per group.  Pigs were taken into the BL2 Livestock Infectious Disease Isolation Facility 
(LIDIF) and weighed.  Pigs were housed in three separate pens in the same room.  Groups 1 
and 2 shared a pen, groups 3 and 4 shared the second pen, and groups 5 and 6 shared the third 
pen (see Table 1).  Pigs in each pen had no nose to nose contact with pigs in the other two 
pens.  Blood was collected 3 days prior to immunization (Day -3) and tested by 
hemagglutination-inhibition assay for antibodies against A/Wyoming/03/2003. 
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Immunizations: 
For vaccine treatment administered on Day 0, VRP lysate was sent from AlphaVax, Inc. 
(Research Triangle Park, North Carolina).  For vaccine treatment administered on Days 21 
and 49, VRP lysate was prepared at Iowa State University.  Samples of lysate used for all 
treatments were run in western blot to confirm the presence of influenza HA protein (see 
Figure 11).  
Formulations were held on ice and administered to pigs within 1 hour.  The doses of 
VRPs given are shown in Table 1.  Pigs were immunized on Days 0 and 21, and 49 (see 
Table 1).  Groups received ≤ 25µg protein/dose for all immunizations.  A total volume of 
1.25mL was given to each pig per dose for all immunizations.  Sterile PBS (pH 7.2, without 
Mg2+ and Ca2+, Sigma, St. Louis, MO) was added to all vaccine formulations to achieve a 
total volume of 1.25mL.  For pigs vaccinated with HA or PRRS protein plus MVP 
Emulsigen-D adjuvant, protein lysate was added to the adjuvant at a ratio of 80:20, for a total 
volume of 1.25mL per dose.  For pigs vaccinated with HA or PRRS protein plus VRP 
adjuvant, 108 infectious units (IU) of VRP were added to each vaccine dose, for a total 
volume of 1.25mL per dose.  Following the first immunization, blood was collected on days 
14, 28, 35, 48, 56, and 68. 
 
Virus challenge: 
On Day 63, pigs weighing approximately 100-120 lbs were held upright, and a 16 inch 
catheter tube (Davol, Cranston, RI) was inserted into the pigs’ tracheas.  Virus previously 
prepared in MDCK cells was used for challenge.  Ten milliliters of virus at a concentration of 
106 TCID50/mL was injected into each pig’s lungs through the catheter tube.  Nasal swabs and 
rectal temperatures were recorded for the following four days post challenge.  Nasal swabs 
were collected in sterile PBS supplemented with 0.2% gentamicin (100mg/mL) and 2% 
penicillin-streptomycin solution (10,000units/mL). 
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Necropsy: 
On Day 68, pigs were euthanized using intravenous Sleepaway and weighed, followed by 
exsanguination.  Blood was collected in SST Plus blood collection tubes.  Serum was 
collected as stated above and frozen at -20ºC for storage.  Lungs were removed and inspected 
for influenza lesions.  No apparent lesions were present.  Bronchoalveolar lavage fluid was 
collected by pipetting 25 mL of lavage fluid (MEM media supplemented with 0.1% 
gentamicin (100mg/mL) and 1% penicillin-streptomycin solution (10,000units/mL)) into 
each set of lungs, gently massaging lungs, and collecting approximately 3-12 mL lavage 
fluid.  Lavage fluid was stored at -80ºC.  Samples of lung tissue from each pig were collected 
in formalin for histopathology and immunohistochemistry and in sterile whirlpak bags for 
virus isolation or PCR.  Lung tissue in bags was stored at -80ºC. 
 
 
Table 1: Experimental design for Trial I. 
Group # 
(5 pigs/group) 
Subunit 
Treatment 
Routea Treatment Dose on 
Days 0, 21 and 49  
(µg  protein/dose)b  
Virus Challenge 
Dose on Day 63  
(106 TCID50 /mL) 
1 PRRS lysate 
 
IM ≤ 25 10 mL, 
intratracheal 
2 V3014 HA lysate 
 
IM ≤ 25 10 mL, 
intratracheal 
3 PRRS lysate + 
MVP adjuvant 
IM ≤ 25 10 mL, 
intratracheal 
4  V3014 HA lysate 
+  
MVP adjuvant 
IM ≤ 25 10 mL, 
intratracheal 
5 PRRS lysate +  
 V3014 HA VRP 
IM ≤ 25 10 mL, 
intratracheal 
6 V3014 HA lysate + 
PRRS VRP 
IM ≤ 25 10 mL, 
intratracheal 
a Pigs were vaccinated intramuscularly (IM) in the ham. 
b HA protein concentration of the HA lysate for the dose given on Day 0 was determined to be 25  
   µg/dose of 0.714 mL.  The PRRS protein concentration and the HA protein concentration for  
   Days 21 and 49 were not determined, but thought to be ≤ 25 µg/dose. 
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Preparation of Challenge Virus: 
Madin Darby canine kidney (MDCK) cells (passage 63) were obtained from Dr. Pravina 
Kitikoon, Thacker Lab, Iowa State University, Ames, Iowa.  Cells were originally received 
from the American Type Culture Collection.  Cells were propagated in growth media 
consisting of 1x MEM supplemented with 6% fetal bovine serum (FBS), 1% L-glutamine, 
1% penicillin-streptomycin, and 0.1% gentamicin.  When cells reached approximately 95% 
confluency, the monolayer was washed twice with sterile phosphate buffered saline (PBS) 
pH 7.2.  Infecting media consisting of 1x MEM supplemented with 6% bovine serum 
albumin (BSA), 1% L-glutamine, 1% penicillin-streptomycin, 0.1% gentamicin and 1µg/mL 
of TPCK treated trypsin was added to cells.  Virus was then added to cells at a concentration 
of 105 to 106 infectious particles per flask in a volume of no less than 100µL per flask.  Cells 
were incubated at 37ºC, 5% CO2.   
When 50% to 70% of virally infected cells had lifted off of the flask, virus was 
harvested.  First, flasks of virally infected cells were placed at -80ºC until the media was 
completely frozen.  Flasks were then removed from the freezer and allowed to thaw at room 
temperature.  Cell debris was clarified by centrifuging the cell media for 15 minutes at 
~2,000 x g, 4ºC.  Supernatant containing virus was stored at -80ºC. 
 
Virus Isolation/Titration: 
Virus was isolated and viral titrations performed as previously described52.  Briefly, MDCK 
cells were propagated in 96-well cell culture plates as described above, with 100mL of media 
per well.  Samples (either bronchoalveolar lavage fluid, nasal swab fluid, or virus previously 
grown in eggs or MDCK cells) containing unknown amounts of virus were serially diluted 
10-fold in infecting media, and 100µL of each dilution was plated into each well.  Positive 
and negative controls were included on each plate.  Plates were incubated at 37ºC, 5% CO2 
for 36 to 40 hours.  Plates were then stained using a protocol as previously described52.   
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Western Blot: 
All western blots were run under non-reducing conditions using 12 well, 4%–12% NuPAGE 
Novex Bis-Tris Gels (Invitrogen, Carlsbad, CA) in a XCell Sure Lock Electrophoresis Cell 
(Invitrogen, Carlsbad, CA).  Serum or bronchoalveolar lavage fluid from pigs was tested for 
the presence of antibody against the hemagglutinin protein of influenza 
A/Wyoming/03/2003.  Whole influenza A/Wyoming/03/2003 virion particles were used as 
protein samples, and serum or bronchoalveolar lavage (BAL) fluid was used as primary 
antibody in each western blot.  
Samples were prepared by mixing 15µL of Influenza A/Wyoming/03/2003 with 
7.5µL of NuPAGE LDS sample buffer 4x (Invitrogen, Carlsbad, CA) and 7.5µL of deionized 
water for each sample.  Samples were then placed in boiling water for 5 minutes.  1x 
NuPAGE MES SDS buffer was prepared according to manufacturer’s instructions 
(Invitrogen, Carlsbad, CA).  10µL of SeeBLUE Plus 2 Ladder (1x) (Invitrogen, Carlsbad, 
CA) was run in each gel.  25µL of sample was then added to each respective well.  Influenza 
A/Wyoming/03/2003 was used as the positive control, and swine serum previously shown to 
contain no antibodies against A/Wyoming/03/2003 was used as the negative control.  
Samples were run at 200V constant, for 50 minutes.   
 Transfer pads and blotting filter paper were soaked for 30 minutes in transfer buffer 
(0.025M BisTris, 0.025M Bicine, 0.001M EDTA disodium salt, and 10% methanol in 
filtered, deionized water).  PVDF membrane (Millipore, Billerica, MA) was soaked in 100% 
methanol for 15 seconds, and then placed in transfer buffer for 30 minutes.   
 When samples had completed running in the gel, the transfer pads, filter paper, PVDF 
membrane and gel, were placed in the transfer apparatus according to manufacturer’s 
instructions (Bio-Rad Laboratories, Hercules, CA), the inner chamber of the blot apparatus 
was filled with transfer buffer, and the outer chamber was filled with deionized water.  The 
transfer was performed at 170mA constant, for 75 minutes.   
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 Immediately following transfer, SeeBLUE ladders were separated from the PVDF 
membrane, then the membrane was cut into strips and placed in blocking buffer (wash buffer 
containing 5% non-fat evaporated milk) on a rocker for 1 hour at room temperature.  
Following blocking, each strip was placed in primary antibody solution (1:100 dilution of 
serum or BAL in blocking buffer) on a rocker for 18-24 hours at 4ºC.  
 Primary antibody was removed and each strip was washed 3 times with wash buffer 
(0.0015M KH2PO4, 0.02M Na2HPO4 dibasic anhydrous, 0.134M NaCl, 0.0027M KCl, and 
0.05% Tween-20 in filtered, deionized water) for 10 minutes on a rocker.  Strips were then 
placed in secondary antibody solution (1:2000 dilution of horse-radish peroxidase labeled α-
swine immunoglobulin (will detect all swine immunoglobulins) in blocking buffer) on a 
rocker for 1 hour at room temperature.  Secondary antibody was removed and each strip was 
washed 3 times with wash buffer for ten minutes on a rocker.   
 Proteins were analyzed using KPL peroxidase substrate solution (Kirkegaard & Perry 
Laboratories, Inc., Gaithersburg, MA) according to manufacturer’s instructions.  Strips were 
soaked in the substrate solution for approximately 3 minutes for serum samples and 12 
minutes for BAL samples, then immediately placed in deionized water.  Strips were allowed 
to dry, then the membrane was reassembled and protein bands were analyzed. 
 
Virus Propagation for Hemagglutination Inhibition Assay: 
Influenza virus A/Wyoming/03/2003 (H3N2) was obtained from the Centers for Disease 
Control (Atlanta, GA).  Embryonated chicken eggs, approximately 11 days old, were 
purchased from the National Veterinary Services Laboratories (Ames, Iowa).  Eggs were 
candled and marked along the air sac.  An engraver was used to make a hole over the air sac 
of the egg, just large enough to insert a tuberculin syringe needle into the egg.  A tuberculin 
syringe was used to inject 100µL of A/Wyoming virus diluted to 103 infectious particles/mL 
into the chorioallantoic cavity of the egg.  The eggs were sealed and incubated at 37ºC 
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without CO2.  Embryos were checked daily, and any that died within 24 hours were 
discarded.  After 2-3 days, eggs were chilled for at least 4 hours at 4ºC, then virus was 
aseptically harvested by opening the shell over the air sac and pipetting out the clear allantoic 
fluid containing the virus.  The fluid was pooled and centrifuged for 15 minutes at 750 x g, 
4ºC.  Supernatant containing the virus was collected and stored at -80ºC. 
 
Hemagglutination-Inhibition Assay: 
The hemagglutination inhibition (HI) assay was performed as previously described83.  
Briefly, turkey erythrocytes diluted 1:1 in Alsever’s solution were purchased from the 
National Veterinary Services Laboratories (Ames, Iowa).  Upon arrival, turkey erythrocytes 
were washed three times in sterile PBS (pH 7.4) by adding approximately 30 mL PBS to 15 
mL erythrocyte solution, gently inverting to mix, then centrifuging for 10 minutes at ~370 x 
g, 4ºC.  After the third wash, a 0.4% erythrocyte solution was made and stored for a 
maximum of seven days at 4ºC for use in the HI assay.  The remaining erythrocyte pellet was 
stored for a maximum of seven days at 4ºC for use in the treatment of serum. 
Serum collected from pigs was diluted 1:3 in receptor destroying enzyme (DENKA, 
Seiken) and allowed to incubate for 18-20 hours at 37ºC.  Serum samples were then heat 
inactivated for 30 minutes at 56ºC, allowed to cool to room temperature, and then diluted to a 
final concentration of 1:9 in sterile PBS (pH 7.4).  Washed, packed turkey erythrocytes were 
added to each sample at a concentration of 1:20.  Serum plus erythrocytes were mixed by 
pipetting, then allowed to incubate at room temperature for 30 minutes.  The serum mixture 
was then centrifuged for five minutes at approximately 12,000 x g on a table top centrifuge.  
Serum was pipetted off of the erythrocyte pellet into clean microcentrifuge tubes and serum 
samples were stored at 4ºC for use within the next 5 days, or placed at -20ºC for extended 
storage. 
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  Hemagglutination was performed using 0.4% turkey erythrocytes and four 
hemagglutinating units of influenza virus A/Wyoming/03/2003. The A/Wyoming 03/2003 
virus was obtained from the Centers for Disease Control (Atlanta, GA) and grown in eggs 
prior to use. A titer ≥ 1:40 was considered positive. 
 
Hemagglutinin ELISA: 
The hemagglutinin ELISA was preformed at AlphaVax, Inc. (Research Triangle Park, NC).  
Serum samples collected from pigs were sent on ice to AlphaVax.  To measure antigen-
specific humoral immune responses to HA in animals immunized with the HA-VRP vaccine, 
purified recombinant HA antigen derived from A/Wyoming/03/2003 (Protein Sciences Inc) 
was used in an ELISA.  Briefly, 96-well Maxisorp ELISA plates (Nunc, Naperville, IL) were 
coated with 50 ng/well of recombinant HA protein in carbonate buffer.  After overnight 
incubation at 4ºC, unbound antigen was discarded and each well was incubated for 1 hr with 
blocking buffer (PBS containing 3% bovine serum albumin) at room temperature.  After 
washing 6 times with PBS, test sera that were serially 2-fold diluted in diluent buffer (PBS 
with 1% BSA and 0.05% Tween-20) were added in triplicate to antigen-coated wells.  
Antigen-coated wells that received no serum served as background controls.  Plates were 
incubated for 1 hour at room temperature, then rinsed six times with PBS.  Alkaline 
phosphatase-conjugated anti-pig IgG (whole molecule) antibody (Sigma, St. Louis, MO) was 
added to each well and incubated for 1 hr at room temperature.  Wells were rinsed again six 
times with PBS before addition of alkaline phosphatase substrate and chromogen.  Samples 
were read at 405 nm on a PowerWave 200 Microplate Scanning Spectrophotometer (BioTek 
Instruments, Winooski, VT).  Endpoint titers were calculated using SOFTmax (Molecular 
Device Corp., Menlo Park, CA), and mean antibody titers were determined for each group.  
Titers are reported as the reciprocal of the serum dilution at which the A405 is ≥ 0.2. 
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Reverse Transcriptase Polymerase Chain Reaction (RT-PCR): 
RT-PCR was performed on nasal swabs to detect influenza A virus (H3N2) antigen.  Nasal 
swab samples collected in 1mL sterile PBS supplemented with 0.2% gentamicin (100mg/mL) 
and 2% penicillin-streptomycin solution (10,000units/mL) were removed from the -80ºC 
freezer and thawed.  Samples were vortexed for 30 seconds two times, then swabs were 
removed from the samples and samples were centrifuged for five minutes at approximately 
12,000 x g on a table top centrifuge.   Most of the supernatant was removed from the sample, 
except for approximately 100µL of fluid along with any pellet that may have formed.  Total 
RNA was then extracted from each 100µL sample using the RNeasy Mini Kit (Qiagen, 
Germantown, MD) according to the protocol “Purification of Total RNA from Animal Cells 
Using Spin Technology.”  For the first step, 400µL of RLT buffer was added to each sample, 
then vortexed for 20 seconds to homogenize the sample.  The protocol was then followed 
from step two according to manufacturer’s instructions.  RNA samples were eluted in 30µL 
of RNase-free water.  A positive control consisting of 50µL of influenza 
A/Wyoming/03/2003 and negative control consisting of buffers from the RNeasy Mini Kit 
were extracted with the samples.   
Reverse transcriptase polymerase chain reaction (RT-PCR) was performed as follows.  
Previously published primers specific for the HA gene, subtype H3, of influenza A viruses140 
were used to amplify the HA gene of influenza.  Primers were provided by Dr. Pravina 
Kitikoon, Thacker Lab, Iowa State University, Ames, Iowa.  Reverse transcriptase PCR was 
set up in 25µL reactions using the Qiagen OneStep RT-PCR kit according to manufacturer’s 
instructions.  Five microliters of RNA was used for each reaction.  RT-PCR was performed 
using the GeneAmp PCR System 9700 (PE Applied Biosystems, Foster City, CA).  Cycling 
conditions were as follows: 1 cycle at 50ºC for 30 minutes; 1 cycle at 95ºC for 15 minutes; 
40 cycles at 94ºC for 1 minute, 55ºC for 45 seconds, 72ºC for 2 minutes; 1 cycle at 72ºC for 
10 minutes; infinite hold at 4ºC.    
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 DNA samples were run in an E-Gel, 2% agarose (GP) (Invitrogen, Carlsbad, CA) 
according to manufacturer’s instructions.  DNA was visualized using Quantity One software 
(Bio-Rad Laboratories, Hercules, CA).   
 
Histopathology and Immunohistochemistry: 
Histopathology and immunohistochemistry were performed by Dr. Bruce Janke (Iowa State 
University, Ames, IA) as previously described92.     
 
Statistics: 
Tukey-Kramer HSD analysis was used to compare HI titers of pigs by group for each day 
that blood was collected.  In order to allow for log transformation of titers with a value of 0, 
an arbitrary value of 0.5 was added to all HI titers, and then titers were log10 transformed, and 
analysis was preformed on log transformed data.  Analysis was conducted using the 
statistical software JMP 6.0.0 (SAS Institute, Cary, NC). 
 
Results 
In our trial, 4 of 30 pigs had an initial maternal HI antibody titer of 1280 against influenza 
A/Wyoming/03/2003, while the other 26 pigs tested negative (titers = 0) for maternal 
antibody by HI assay (data not shown).  Pigs with maternal antibody were placed in a single 
group (Group 5, pigs vaccinated with PRRS lysate + V3014 HA VRP) and the other pigs 
were randomly assigned to the remaining five groups.  Figure 1 shows the geometric mean 
titers of pigs by group for Groups 1-4.   
Data from groups 1, 2, 3, 4, and 6 were used in the statistical analysis for this trial.  
Data from Group 5 was omitted from analysis due to the fact that 4 of the 5 pigs in Group 5 
were not randomly assigned to the group.  There was no significant difference in HI titers 
between any of the five groups analyzed on any of the days using Tukey-Kramer HSD 
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analysis.  However, results of the statistical analysis were suggestive that the group 
administered HA protein + Emulsigen-D adjuvant (Group 4) had significantly higher HI 
titers than any of the other groups (data not shown), but further work is needed to confirm 
this suggestive data.    
 
 Figures 2, 3, 4, and 5 show HA ELISA titers on Days 56 and 68 for pigs vaccinated 
intramuscularly (IM) with influenza HA protein lysate alone, HA protein lysate plus MVP 
Emulsigen-D adjuvant,  PRRS virus protein lysate plus HA-VRP, or HA protein lysate plus 
PRRS-VRP, respectively.  ELISA OD405 values from serum of pigs collected on Day -3 were 
used as baseline or “negative” values to calculate ELISA titers on Days 56 and 68.  Pigs 133, 
134, and 135 had maternal antibody against A/Wyoming with ELISA titers of > 40 on Day -3 
(Figure 9).  The other 27 pigs had HA ELISA titers of < 40 on Day -3.  Pig 136 was shown to 
have maternal antibody by HI assay, but not by ELISA.  HA ELISA titers were negative 
(titers < 40) for all pigs vaccinated with PRRS protein lysate alone, or with PRRS protein 
lysate plus MVP Emulsigen-D adjuvant (groups 1 and 3) on both Days 56 and 68 (data not 
shown).   
 In Figure 2, one pig of five vaccinated with HA protein lysate alone demonstrated a 
response to vaccination by ELISA by Day 56, and two pigs of five demonstrated a response 
by Day 68, but responses in both pigs were low (titers ≤ 80) when compared to other groups 
of pigs in the trial.  In Figures 3, 4, and 5, five of five pigs in all three groups demonstrated 
an ELISA response to vaccination on both days (titers ≥ 80).  Pigs vaccinated with HA 
protein lysate plus MVP Emulsigen-D adjuvant (Figure 3) had the highest ELISA titers of all 
groups in Trial I, with titers of all pigs ≥ 1280 on both Days 56 and 68. 
 
Figure 6 shows the western blot of the HA protein used to vaccinate pigs in Trial I.  
Total protein in each sample was determined (Table 2) using the RC DC Protein Assay kit 
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according to manufacturer’s instructions (BioRad, Hercules, CA).  Protein bands at 75 kDa 
show the location of the HA0 molecule (Figure 6). 
Table 3 shows western blot data from serum or bronchoalveolar lavage (BAL) fluid 
from pigs in each group.  Samples were tested for the presence of antibodies against 
A/Wyoming/03/2003.  Pigs vaccinated with PRRS lysate alone, with V3014 HA lysate alone, 
or with PRRS lysate plus MVP Emulsigen-D adjuvant had no detectable antibody against 
A/Wyoming HA protein in both serum and BAL fluid on Days 56 and 68.  Two of five pigs 
had detectable serum antibody on Day 68 in pigs vaccinated with HA lysate plus PRRS-
VRP, but no antibody was detected in the serum of these pigs on Day 56 or in the BAL fluid 
on Day 68.  Antibody was detected in the serum of all five pigs vaccinated with HA lysate 
plus MVP Emulsigen-D adjuvant and all five pigs vaccinated with PRRS lysate plus HA-
VRP on both Days 56 and 68.  Antibody was detected in the BAL fluid of all five pigs 
vaccinated with HA lysate plus MVP Emulsigen-D adjuvant and four of five pigs vaccinated 
with PRRS lysate plus HA-VRP on Day 68. 
 
Histopathology and immunohistochemistry on lung tissues samples from all pigs in 
this trial were performed by Dr. Bruce Janke (Iowa State University, Ames, Iowa).  No 
conclusive lesions were observed in any of the lung tissue samples from any pigs in any of 
the groups.  Similarly, no virus was detected in lung tissue samples via 
immunohistochemistry in any pigs in this trial. 
 
No live virus was detected by virus isolation in MDCK cells in any of the 
bronchoalveolar lavage fluid samples collected at necropsy from any pigs in this trial.  Table 
4 shows RT-PCR data from nasal swabs collected from pigs 1, 2, and 3 days post challenge.  
At 1 day post challenge (Day 64), virus was detected in the nasal swabs from 4 of 30 pigs, 2 
pigs who had been vaccinated with HA protein lysate alone (pigs 117 and 129), and 2 pigs 
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who had been vaccinated with PRRS protein lysate plus V3014 VRP (pigs 133 and 135).  At 
2 days post challenge (Day 65), virus was detected in the nasal swabs from 2 of 30 pigs, 1 
pig who had been vaccinated with HA protein lysate alone (pig 117), and 1 pig who had been 
vaccinated with HA protein lysate plus PRRS VRP (pig 125).  At 3 day post challenge (Day 
66), virus was detected in the nasal swabs from 6 of 30 pigs, 2 pigs who had been vaccinated 
with HA protein lysate alone (pigs 117 and 129), 2 pigs who had been vaccinated with PRRS 
protein lysate plus MVP Emulsigen-D adjuvant (pigs 122 and 126), and 2 pigs who had been 
vaccinated with PRRS protein lysate plus V3014 VRP (pigs 133 and 135).   
  
 Figure 7 shows average body temperatures of pigs, by group, from one day before 
and four days after virus challenge.  Average temperatures for groups 3 and 4 declined from 
the first day temperatures were taken (one day prior to challenge) to two days after challenge.  
Groups 1, 2, 5, and 6 all showed a slight increase in temperature from one day prior to 
challenge to one day after.  Pigs in all groups maintained a steady average temperature from 
two to four days post challenge.   
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Figure 1: Trial I - Hemagglutination-Inhibition geometric mean titers (GMT) of 
pigs by group.  Group 1: PRRS, Group 2: HA, Group 3: PRRS + MVP, Group 4: 
HA + MVP, Group 5: not shown, Group 6: not shown.  GMT were calculated by 
taking the log10(HI titers + 0.5) of pigs on all days, then calculating the mean of 
the logs.  Error bars represent 95% confidence interval.  
 
 
 
Figure 2: HA ELISA titers for Trial I, group 2, pigs vaccinated 
intramuscularly in the ham with ≤ 25 µg V3014 HA protein lysate on 
Days 0, 21 and 49. ELISA titers are defined as the reciprocal of the 
highest dilution of serum for which the optical density was ≥ 2 times the 
optical density of serum diluted 1:40 from Day -3. 
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Figure 3: HA ELISA titers for Trial I, group 4, pigs vaccinated 
intramuscularly in the ham with ≤ 25 µg V3014 HA protein lysate plus 
MVP Emulsigen-D adjuvant on Days 0, 21 and 49. ELISA titers are 
defined as the reciprocal of the highest dilution of serum for which the 
optical density was ≥ 2 times the optical density of serum diluted 1:40 
from Day -3. 
 
 
 
Figure 4: HA ELISA titers for Trial I, group 5, pigs vaccinated 
intramuscularly in the ham with ≤ 25 µg PRRS virus protein lysate 
(negative control) plus 2.1 x 108 IU/mL of V3014 HA-VRP on Days 0, 
21 and 49.  Pigs 133, 134, and 135 had an ELISA titer of >40 on Day -3 
(considered cutoff point for positive titer), but exact titers were not 
determined for these pigs on Day -3. ELISA titers are defined as the 
reciprocal of the highest dilution of serum for which the optical density 
was ≥ 2 times the optical density of serum diluted 1:40 from Day -3. 
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Figure 5: HA ELISA titers for Trial I, group 6, pigs vaccinated 
intramuscularly in the ham with ≤ 25 µg V3014 HA protein lysate plus 
8.8 x 108 IU/mL of PRRS-VRP on Days 0, 21 and 49. ELISA titers are 
defined as the reciprocal of the highest dilution of serum for which the 
optical density was ≥ 2 times the optical density of serum diluted 1:40 
from Day -3. 
 
 
 
Figure 6: Western blot of influenza A/Wyoming/03/2003 HA protein lysate 
used as vaccine for pigs in Trial I.  The influenza HA protein (HA0) is 
approximately 75 kDa in size (bands inside black box).  V3014 HA lysate 
from AlphaVax was used to vaccinate pigs on Day 0.  V3014 HA lysate 
prepared 7/24/2006 was used to vaccinate pigs on Day 21.  V3014 HA 
lysate prepared 9/22/2006 was used to vaccinate pigs on Day 49.   
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Table 2: Total protein concentration of HA   
lysate used to vaccinate pigs in Trial I. 
Sample Total Protein 
(mg/mL) 
V3014 HA lysate from 
AlphaVax 
1.112 
 
V3014 HA lysate 
prepared 7/24/2006 
0.577 
V3014 HA lysate 
prepared 9/22/2006 
0.581 
 
 
Table 3: Trial I western blot data showing presence or absence of antibodies 
against A/Wyoming hemagglutinin in serum or BAL fluid of pigs. 
Group # 
(5 pigs/ 
group) 
Subunit 
Treatment 
Day 56a  
HA antibody 
in serum 
Day 68b  
HA antibody 
in serum 
Day 68c  
HA antibody 
in BAL fluid 
1 PRRS lysate 
 
0/5 0/5 0/5 
2 V3014 HA lysate 
 
0/5 0/5 0/5 
3 PRRS lysate + 
MVP adjuvant 
0/5 0/5 0/5 
4  V3014 HA lysate 
+  
MVP adjuvant 
5/5 5/5 5/5 
5 PRRS lysate +  
 V3014 HA VRP 
5/5 5/5 4/5 
6 V3014 HA lysate +  
PRRS VRP 
0/5 2/5 0/5 
a,b,c Serum or bronchoalveolar lavage (BAL) fluid samples from pigs vaccinated 
with either PRRS lysate or HA lysate, with or without adjuvant, were tested via 
western blot for the presence of HA-specific antibodies. Values are reported as 
number of pigs positive for HA antibody/ total number of pigs per group.  
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Table 4: Trial I RT-PCR data showing presence or absence of A/Wyoming antigen 
in nasal swabs of pigs 1-3 days post challenge. 
Group # 
(5 pigs/ 
group) 
Subunit 
Treatment 
Day 64a  
Pigs Positive 
for Viral 
RNA  
Day 65b  
Pigs Positive 
for Viral 
RNA 
Day 66c  
Pigs Positive 
for Viral 
RNA 
1 PRRS lysate 
 
Negative Negative Negative 
2 V3014 HA lysate 
 
117 
129 
117 117 
129 
3 PRRS lysate + 
MVP adjuvant 
Negative Negative 122 
126 
4  V3014 HA lysate 
+  
MVP adjuvant 
Negative Negative Negative 
5 PRRS lysate +  
 V3014 HA VRP 
133 
135 
Negative 133 
135 
6 V3014 HA lysate +  
PRRS VRP 
Negative 125 Negative 
a,b,c RT-PCR was performed on RNA extracted from nasal swabs of pigs 1, 2, and 3 
days post-challenge (Days 64, 65, and 66). “Negative” indicates that no virus was 
detected in any of the pigs on that day via RT-PCR.  Pig number indicates that a 
pig did contain virus in its nasal swab via RT-PCR.  
 
 
 
Figure 7: Trial I - Group average body temperatures 1 day before and 
4 days post-challenge.   
 
  
Discussion 
Our purpose for Trial I was to evaluate the ability of recombinant hemagglutinin (rHA) 
protein produced in vitro in Vero cells from alphavirus replicons to elicit an immune 
response in pigs.  We also wanted to evaluate the ability of a response elicited by replicon-
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derived HA protein to protect pigs from challenge with live A/Wyoming/03/2003 influenza 
virus.  Based upon hemagglutination-inhibition (HI), ELISA, and western blot data, we have 
suggestive evidence that protein derived from Venezuelan equine encephalitis virus replicon 
particles is able to elicit an immune response in pigs.  Based upon HI data, development of 
an immune response in pigs to the rHA protein took longer than expected.  This delay in 
response may be due to a number of factors including amount of rHA protein administered to 
each pig and dosing schedule.  The amount of rHA protein in the first dose was 25µg of 
protein as determined at AlphaVax by densitometry analysis.  However, the exact amount of 
rHA protein for the second and third vaccinations was not determined.  Figure 6 shows that 
rHA protein was present in all vaccination formulations, but Table 2 shows that total protein 
was lower for the second and third vaccinations; therefore the amount of rHA protein 
administered to those pigs was most likely less than 25µg.  In humans, a dose of 45µg of 
rHA protein produced from baculovirus vectors has been selected to use as a commercial 
vaccine66.  It is possible that a larger amount of rHA was needed to elicit a stronger and more 
rapid immune response in pigs.      
 Influenza A/Wyoming/03/2003 was used as the human vaccine strain for the 2004-
2005 flu season44.  Replicons expressing the HA gene of this virus had previously been 
constructed by AlphaVax Inc., therefore these replicons were used for initial testing in pigs.  
It was not known if A/Wyoming would be able to efficiently infect and cause disease in pigs.    
Based upon histopathology, immunohistochemistry, and viral titrations from bronchoalveolar 
lavage (BAL) fluid, it does not appear that the virus was able to cause disease in these pigs. 
Reverse transcriptase PCR results from Table 4 demonstrate that A/Wyoming was able to 
replicate, even if at a low level, in pigs.  The negative control pigs vaccinated with PRRS 
protein lysate alone showed no viral shedding in the nasal swabs.  Because of these results, 
we were not able to determine if the immune response elicited by the rHA protein was able to 
protect pigs from virus challenge.  It cannot be determined from this trial if the A/Wyoming 
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virus is able to cause disease in pigs for several reasons.  At the time of virus challenge, pigs 
were 12 weeks old and weighed approximately 100 to 120 pounds.  It is difficult to cause 
clinical disease in pigs of this size, and pigs weighing around 50 to 75 pounds are preferred 
for demonstrating lung lesions and viral shedding after challenge117.  Also, ten milliliters of 
virus at a concentration of 106 TCID50/mL was injected into each pig’s lungs, and due to the 
large size of the pigs at time of challenge, more virus may have been needed to cause clinical 
disease.   
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CHAPER 5:  GENERAL DISCUSSION 
 
The work presented in this thesis describes the first time viral replicon particles 
derived from Venezuelan equine encephalitis virus (VRPs) have been evaluated for use in 
pigs.  As VRPs had never been used in pigs to express a foreign gene, we wanted to 
determine if the replicons could express a gene of interest that would elicit an immune 
response in pigs.  We also wanted to know if protein produced in vitro from VRPs would be 
able to elicit an immune response in pigs, either alone or in combination with an adjuvant.   
 
From the data described in Chapter 3 of this thesis, it has been shown that VRPs can 
elicit an immune response to a gene of interest in pigs.  Two separate trials were conducted in 
which VRPs expressing the influenza hemagglutinin (HA) gene were evaluated in pigs.  In 
Trial I, we used VRPs derived from Venezuelan equine encephalitis virus (VEE) strain 
V3014 to vaccinate pigs intramuscularly with different concentrations of the replicon.  Due 
to the presence of maternally derived antibodies (MDA) against A/Wyoming in 23 of 24 
pigs, further work was needed to determine if the response seen in this one pig was 
representative of a larger portion of the swine population.  Other pigs in the study did appear 
to respond to vaccination following decay of their MDA (data not shown) and more pigs may 
have responded if dosing schedule and amount of VRP administered were optimized.   
In Trial II, we used VRPs derived from either V3014 or TC-83 to vaccinate pigs 
intramuscularly or intranasally against A/Wyoming/03/2003.  Based upon hemagglutination-
inhibition (HI) and ELISA titers, we showed that the intramuscular (IM) route of vaccination 
was more effective at eliciting an immune response against HA than the intranasal (IN) route 
when vaccinating with VRPs.  We also showed that VRPs derived from either TC-83 or 
V3014 appeared to be equally efficient at expressing the HA protein in vivo, as no significant 
difference was observed in immune responses between pigs vaccinated with either of these 
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VRPs.  Because V3014 is considered a select agent, VRPs derived from this VEE virus strain 
must be constructed under Biosafety-level 3 conditions.  Replicons constructed from TC-83 
may be constructed under Biosafety-level 2 conditions; therefore the use of TC-83 to 
construct VRPs is desirable in that production costs are less for VRPs derived from TC-83 
than for VRPs derived from V3014.  In addition, results from Trial II provide information to 
conclude that the results seen in Trial I for pig 24 (no maternal antibody against A/Wyoming) 
are not unique to that one animal, and can be repeated.   
Although the sample size of pigs is not large enough to make any specific conclusions 
about whether or not VRPs can illicit an immune response in pigs against HA in the presence 
of MDA, it is interesting to note that most pigs in Trial II with an initial MDA titer against 
A/Wyoming and vaccinated either IM or IN with HA-VRPs maintained HI titers ≥ 40 
throughout most or all of the study (data not shown).  Pigs in the negative control Gag-VRP 
groups that had an initial maternal antibody titer against A/Wyoming all reached HI titers ≤ 
20 by Day 52.  Further work is needed to evaluate the ability of VRPs derived from VEE to 
protect pigs from influenza challenge in the presence of MDA. 
 
Work described in Chapter 4 suggests that protein derived from VRPs expressed in 
vitro is able to elicit an immune response in pigs when administered in combination with an 
adjuvant.  Based upon HI data, development of an immune response in pigs to the rHA 
protein took longer than expected.  This delay in response may be due to a number of factors 
including amount of rHA protein administered to each pig and dosing schedule. The amount 
of rHA protein in the first dose was 25µg of protein as determined at AlphaVax by 
densitometry analysis.  However, the exact amount of rHA protein for the second and third 
vaccinations was not determined.  In humans, a dose of 45µg of rHA protein produced from 
baculovirus vectors has been selected to use as a commercial vaccine66.  It is possible that a 
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larger amount of rHA was needed to elicit a stronger and more rapid immune response in 
pigs. 
The Influenza A virus hemagglutinin (HA) gene was selected as the gene of interest 
to use in pigs for several reasons.   Influenza is common respiratory pathogen that has had 
significant detrimental effects on the swine industry for decades, and current vaccination 
methods are insufficient to provide broad heterologous protection against the newly 
emerging reassortant virus strains.  Secondly, the HA protein is found on the surface of the 
virus and antibody against this protein has been shown to be protective against virus 
challenge66, 93, 113.  Future work may evaluate the ability of VRPs to elicit an immune 
response against other influenza proteins in pigs and against proteins from other swine 
pathogens.  Many questions have arisen from work presented in this thesis.  Is the immune 
response elicited by the VRPs or HA protein able to protect pigs from challenge with virulent 
influenza virus?  Do VRPs have the ability to elicit a protective immune response in the 
presence of maternal antibody?  Can VRPs be used multiple times in a pig without being 
inhibited by VRP neutralizing antibodies?   Further research must be done in order for these 
questions to be answered.      
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